annual report 2014 terumo group introduced new corporate logo august 2014 new logo capture vision standing beginning new stage determined build record important accomplishment even preserve value trust built date curved line extending left right symbolizes rising challenge innovation order provide new value medical frontlines red color signifies life patient passion terumos associate shapecalling mind arc eartharticulates speed action global scale green lettering spelling terumo represents value created point new logo terumo associate across globe work concert ensure living corporate mission contributing society healthcare terumo employee called associate emphasize partnership collaborative working terumo corporation 1 annual report 2014 content content editorial policy 2 corporate mission 3 feature article rising challenge innovation 5 message top management 11 business overview 16 financial information 31 corporate governance 42 intellectual property 56 stakeholder 81 environment 122 director audit supervisory board member executive officer 165 major consolidated subsidiary 167 corporate information investor information 169 reporting policy 170 editorial policy report prepared provide stakeholder clear coherent description business activity undertaken fulfill corporate mission contributing society healthcare promote communication society illustration attitude terumo brings fulfilling corporate mission special section provide concrete account interventional therapy reduces burden patient condition surrounding blood transfusion emerging country brochure present mainly information business performance website offer detail environmental social contribution initiative coverage report coverage includes extent possible element global terumo group falling within scope consolidated earnings statement coverage however differs certain instance reporting period report cover activity fiscal 2013 april 1 2013 march 31 2014 however recent activity also included note regarding forwardlooking statement report includes information future plan strategy business performance information represents judgment based information available time prepared change economic condition business environment demand currency exchange rate factor therefore may cause actual business performance differ significantly forecast projection terumo corporation 2 annual report 2014 courtesy kitasato institute archive terumo corporation founded 1921 several scientist doctor including dr shibasaburo kitasato produce clinical thermometer japan vital medical device previously imported cut consequence world war lifelong spirit dr kitasato whose achievement received global recognition found statement scientist never feel selfsatisfaction advanced research true objective result put use thereby contributing society contributing society healthcare terumos starting point unchanging corporate mission keeping dr kitasatos spirit innovation challenge alive strive bring outstanding innovation medicine enable best possible care patient terumo corporation 3 annual report 2014 corporate mission contributing society healthcare contribute society providing valued product service healthcare market responding need patient healthcare professional five statement open management maintain fundamental policy open management work secure return benefactor suitable profit strive develop business global basis befits leading company industry enhanced value emphasize importance scientific thinking creativity time appropriation respond depth customer need creating valued product service safety reliability pride commitment development technology quality assurance system ensure safe reliable product respect associate emphasize respect individual promote intercultural understanding encourage openness workplace accordance slogan associate spirit prepare meet challenge future corporate citizenship conduct business activity fair equitable manner act responsibly toward environment fulfill responsibility good corporate citizen terumo corporation 4 annual report 2014 feature article rising challenge innovation terumo corporation 5 annual report 2014 getting patient cardiovascular disease back daily life quickly possible able get back daily life week go interventional device inserted blood vessel work drive go walk wrist maneuvered heart josias life suburb são paulo brazil long thin balloon metallic tubular mesh routine physical exam december 2013 found one structure called stent used open coronary artery blocked cholesterol blocked blood vessel inside substance preventing sufficient involves much less blood loss blood flow march 2014 josias underwent traditional approach inserting interventional interventional procedure thin tube device groin even performed called interventional device used open outpatient basis therapy approach gaining blocked artery inside restore popularity throughout world promote use normal blood flow afterward josias received therapy place less physical burden positive prognosis patient terumo offering product training type therapy josias received program use location across globe terumo taking innovation pioneering technology raise therapeutic efficacy stent used treat josias called drugeluting stent de coated drug preventing blood vessel narrowing intervention procedure performed terumo working develop new method applying drug stent creating stent better property extending boundary de technology way well latest drug gradually released take effect new generation stent development incorporated new de introduced resorbed inside body european market june 2014 meanwhile ongoing development focusing commercialization new generation stent bioresorbable scaffold resorbed inside body medical professional terumos technology clearly stand market patient used terumos drugeluting coronary stent display favorable clinical result one could say terumos continuous investment prof dr expedito e ribeiro research development contributing greatly associate professor cardiology delivery therapy provides better outcome university são paulo brazil lower physical stress patient director interventional cardiology totalcor hospital sp terumo corporation 6 annual report 2014 feature article rising challenge innovation terumo corporation 7 annual report 2014 system enhance safety medical professional handling anticancer drug cancer chemotherapy anticancer drug used accidental exposure anticancer drug suppress proliferation cancer cell anticancer wellknown time strict measure drug however destroy cancer cell taken mitigate measure however also side effect damage normal cell yet sufficiently implemented japan cause serious health problem include terumo began selling closed infusion system leukemia infertility healthy people enables safe handling anticancer drug congenital birth defect pointed japan asia 2010 2013 respectively health risk particular concern system employ various innovation reduce pharmacist nurse prepare anticancer drug spraying splashing leaking handling administer patient normal part anticancer drug work u europe risk associated terumo taking innovation training healthcare professional anticancer drug exposure prevention terumo conduct practical training inform medical professional health risk arise spraying splashing leaking anticancer drug provide instruction mitigation measure developing shared awareness measure among medical professional involved treatment cancer recognized enhancing safety handling training exercise using fluorescent dye closed infusion system focusing anticancer drug also resulting better care patient simulate spraying splashing safety step preparation ministry health labour welfare may 2014 leaking anticancer drug administration anticancer drug notification prefectural government safety measure handling anticancer drug expected boost awareness important topic cancer treatment setting japan medical professional terumos anticancer drug infusion system various innovation reduce spray splashrisks nurse previously careful preparing administering anticancer drug oncology nurse become ill handling anticancer drug would negative impact patient care significant damage sachiko tachibana operation hospital work considering vice president head nursing university fukui hospital health safety individual medical personnel therefore ultimately protects patient hospital alike terumo corporation 8 annual report 2014 feature article rising challenge innovation terumo corporation 9 annual report 2014 providing safer blood product patient developing nation africa blood product used transfusion often period time blood collection recent year contain residual white blood cell pathogen terumo focused understanding virus bacteria example ghana 10 pathogen reduction technology prt system could 15 whole blood product contaminated used improve safety blood product bacteria 50 contain malaria plasmodium developing nation terumos prt system us parasite africa whole estimate ultraviolet light riboflavin vitamin b2 naturally 5 10 new hiv infection due unsafe occurring substance reduce pathogen load blood global level world health organization virus eg hiv bacteria parasite eg malaria belief better blood safety strategy inactivate residual white blood cell system could prevent 160000 new case hiv annually already used several developed county testing pathogen africa prevalent process platelet plasma product existing testing method always adequate terumos prt system conformance medical device directive available select market however terumos prt system detect bacteria virus dormant sale u terumo taking innovation reduce pathogen load blood product make safe patient terumo embarked clinical trial ghana support future implementation prt whole blood transfusion believe prt system prove valuable resource patient developing nation terumos pathogen reduction technology prt system medical professional clinical trial provide evidence may greatly advance provision safe blood ghana developing country terumos prt system shown effective could significantly improve safety whole blood maternal hemorrhage malarial anemia dr shirley owusuofori transfusion medicine specialist many clinical condition hopeful head transfusion medicine terumos prt system minimize residual risk unit komfo anokye teaching hospital highprevalence infection pathogen malaria universal screening currently exists terumo corporation 10 annual report 2014 message top management continuing contribution globalized healthcare terumo established 1921 improve public health making highquality thermometer today motivation life corporate mission contributing society healthcare globalization healthcare driving major change way contribute continue quest deliver new value patient healthcare professional throughout world yutaro shintaku president representative director terumo corporation 11 annual report 2014 recap fiscal 2013 fiscal 2014 agenda accelerating growth boosting profitability fiscal 2013 factor including health insurance reform revision reimbursement price japan u fiscal austerity europe perpetuated additional outlay quality management system downward pressure healthcare expenditure developed improvement fiscal 2014 particularly challenging country time ongoing growth demand profit front response effect swift course medical service emerging country blunted correction aimed achieving high growth profitability growing pressure keep price initiative discussed difficult condition however terumo continued grow contributing greater safety 1 change operation globalized businessled efficiency medical service providing therapy management improve medical cost efficiency reduce burden patient employed matrixstyle management cardiac vascular business example introduced approach business segment along vertical axis new product interventional therapy application function region horizontal april 2014 however expand coronary brain lower adopted globalized businessled management organized extremity laying groundwork launch around three core company cardiac vascular company new coronary intervention product early fiscal 2014 general hospital company blood management looking future technology reduced stress company nine division blood vessel also acquired exclusive acquisition right company manage sale rd production function clarify french venture company developing product profit responsibility speed decision making part general hospital business introduced addition global management key underlying range new product including enhancement theme division headquarters already located offering safely administering drug system equipped place make sense pursuing rd data communication function prevent medical accident production marketing strategy globally device improve efficiency medical setting cardiac vascular company example blood management business globally expanded interventional system division charge product system efficiently process blood preparation interventional therapy coronary heart lower broadened application therapeutic apheresis extremity based japan neurovascular strengthening rd also moved ahead plan create division led u subsidiary microvention inc cv robust production system measure system division overseeing activity field cardiac establishment new factory vietnam surgery headed another u subsidiary terumo result activity discussed recorded cardiovascular system corp vascular graft division fiscal 2013 net sale 4674 billion yen 16 year year handle artificial vascular graft used surgical operating income 653 billion yen 23 year year therapy led uk subsidiary vascutek ltd challenge faced include delay ramping general hospital company continue based manufacturing cost reduction new product japan blood management company continuation investment improve quality operation pursued terumo bct inc also management system overseas factory u subsidiary terumo corporation 12 annual report 2014 message top management new globalized businessled management new system based matrix management three company nine division cardiac vascular region function division region function neurovascular division cardiac vascular cv system division vascular graft division general hospital general hospital region function blood management general hospital product division dm consumer healthcare division corporate pharmaceutical nutrition division dd division blood management region function corporate corporate head office meanwhile develop aiming achieve growth profit margin target implement portfolio strategy corporatewide development sale new product transfer perspective enhance corporate function putting production location outside japan activity place infrastructure support global business activity centered mainly division recently june 2014 three core company released new drugeluting stent de ultimaster european market neurovascular division 2 accelerate shift highermargin product focusing new neurovascular intervention device new businessled management approach aim expanding highly profitable dm consumer increase value add strengthening position healthcare division dd division primary focus company area specialty boost profit revising general hospital company also set production system furthermore measure aimed rebuilding reducing cost business profit strengthening increasing efficiency corporate suffered established business structural improvement function corporate head office aim accelerate office also move ahead plan transfer improvement profitability production place outside japan specific level cardiac vascular company blood management company expand business terumo corporation 13 annual report 2014 therapeutic apheresis cell therapy promise future market expansion shift production product global csr initiative including blood bag asia reduce cost meanwhile corporate head office work revamp furtherance corporate mission contributing logistics lower procurement cost newly society healthcare advance communication established procurement dept promotes even greater trust understanding stakeholder customer shareholder employee 3 write asset certain business supplier local community pursue social general hospital company pharmaceutical nutrition environmental initiative business activity division cardiac vascular company cv system csr activity strengthen group legal division recorded extraordinary loss previous compliance system quality management system fiscal year current fiscal year take production setting formulate terumo global ehs inventory business facility step boosting environmental health safety policy take corporate value long term preparing growth action well emphasize global outlook also push ahead development major longterm objective terumo group new product future continue search become company global presence realizing opportunity key people working foster sense fiscal 2014 year securing foothold corporate culture recognizes diversity viewpoint taking decisive step lead future growth promotes development people spirit nearterm goal committed achieving challenge new idea source innovation operating margin 20 excluding goodwill amortization contributing betterment healthcare etc fiscal 2016 direction moving step taking achieve objective described detail operating profit margin target annual report drawing capability aim 200 achieve sustainable profitable growth contribute global healthcare continuous support greatly appreciated move forward 175 170 fiscal 2013 fiscal 2014 fiscal 2016 result forecast outlook operating profit margin amortization goodwill intangible shareholder return aim pay dividend steadily increase reflecting factor performance future investment plan goal mediumtolong yutaro shintaku term call dividend payout ratio 30 president representative director terumo corporation 14 annual report 2014 participation united nation 2012 terumo became signatory united nation global compact action reflects terumos agreement ten principle compact relate human right labor practice environment anticorruption measure terumo given shape mission contributing society healthcare setting five statement formulated 1996 principle guide group global business development make valuable contribution healthcare worldwide going forward terumo continue fulfill responsibility global enterprise aiming achieve sustainable growth ten principle united nation global compact human right principle 1 business support respect protection internationally proclaimed human right principle 2 make sure complicit human right abuse labor principle 3 business uphold freedom association effective recognition right collective bargaining principle 4 elimination form forced compulsory labor principle 5 effective abolition child labor principle 6 elimination discrimination respect employment occupation environment principle 7 business support precautionary approach environmental challenge principle 8 undertake initiative promote greater environmental responsibility principle 9 encourage development diffusion environmentally friendly technology anticorruption principle 10 business work corruption form including extortion bribery terumo corporation 15 annual report 2014 business overview business overview 17 cardiac vascular company 19 general hospital company 23 blood management company 27 terumo corporation 16 annual report 2014 business overview terumo rising challenge innovate three business area terumo contributing society healthcare pursuing business activity three company provide optimal product service medical setting world pursuing higher quality medicine introduce improvement greater safety ease use conduct training promote proper usage device propose system responding comprehensively need medical setting net sale company blood is1 division management company 1413 billion yen 30 927 billion yen cardiac pharmaceutical 20 vascular company nutrition division fiscal 2013 368 billion yen 8 4674 2106 general billion yen billion yen dd division hospital company 45 223 billion yen 5 1641 billion yen neurovascular division 174 billion yen 4 dm consumer 35 healthcare division cv2 system division 241 billion yen 5 404 billion yen 9 general hospital product division 809 billion yen 17 vascular graft division 115 billion yen 2 1 interventional system 2 cardiovascular system net sale geographic area asia others overseas 704 billion yen japan 2783 billion yen europe 15 1891billion yen 60 40 fiscal 2013 969 billion yen 4674 21 billion yen america 1110 billion yen 24 terumo corporation 17 annual report 2014 cardiac vascular company cardiac vascular company strives make interventional procedure surgery treating heart type vascular disease less burden patient cholesterol substance build inside wall blood vessel due cause including lifestyle disease eventually result heart attack angina treated using intervention device open blocked blood vessel inside known coronary intervention surgically opening chest using section blood vessel another part body artificial blood vessel go around location blockagebypass surgery cardiac vascular company strives reduce burden patient improve therapy outcome recently endeavor also come include treatment vascular disease brain lower extremity general hospital company general hospital company contributes higher quality medicine large providing medical device pharmaceutical system designed improve safety convenience medical treatment setting diversified extend hospital patient home medical device pharmaceutical therefore must incorporate performance usage design consideration tailored setting used general hospital company offer series system comprising combination device pharmaceutical optimized patient providing care company provides added value system form greater safety setting medical treatment provided improved efficiency performing treatment procedure blood management company blood management company drive customer value enhances patient outcome blood component therapeutic apheresis cellular technology global leader blood component therapeutic apheresis cellular technology company unique combination apheresis collection manual automated whole blood processing pathogen reduction believe potential blood even patient today belief inspires innovation strengthens collaboration customer terumo corporation 18 annual report 2014 business overview cardiac vascular company vigorous rd strategic alliance creating valuable solution solidifying presence global market shinjiro sato president cardiac vascular company fy 2013 result net sale business billion yen net sale region billion yen net sale 2106 billion yen vascular graft asia others japan 115 54 1413 671 367 174 495 235 cv system fy 2013 fy 2013 operating income 439 billion yen 404 192 2106 2106 neurovascular europe america operating profit margin 21 174 83 590 280 654 311 fiscal 2013 result interventional therapy performed entering blood vessel wrist terumo strongly promoting sale growth led business neurovascular division achieved doubledigit sale growth strong performance growthdriving addition scepter occlusion balloon catheter neurovascular division cardiac vascular company posted fred flow diversion stent new product along 241 yearonyear increase net sale 2106 billion yen mainstay coil treating cerebral aneurysm japan misago peripheral stent hiryu plus turning profit ongoing investment cv system balloon catheter coronary intervention new division improve ann arbor plant quality management therapeutic device led 7 increase sale system line u food drug administration fda outside japan strong sale growth u standard weighed heavily profit nevertheless europe emerging market combined positive divisiona key profit centerrecorded significantly higher exchange rate impact produce 30 increase sale profit result sale growth strict cost control notably strong growth despite global price decline negatively affected neurovascular division division benefitted mainly business condition addition positive exchange growing popularity tri transradial intervention rate impact division strong performance growth forecast neurovascular division neurovascular coilassist stent flow million dollar diversion stent 2000 occlusion balloon peripheral sfa stent carotid artery stent 1500 pta balloon coronary 1000 new de new ptca balloon access device 500 guidewires etc 0 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2016 fy terumo corporation 19 annual report 2014 cardiac vascular company booked overall 51 increase strategy going forward profit 439 billion yen margin 21 pursuing sustainable profitable growth building global capacity key fiscal 2013 initiative first priority pursuing sustainable profitable growth strengthening core business develop business key growth field area pursuing strategic alliance coronary intervention new ultimaster de launched fiscal 2013 year significant progress implementing june 2014 europe part asia result innovative growth strategy particularly division drugeluting design ultimaster offer exceptional deliverability stent des comprise largest segment conformability contributes longterm clinical outcome interventional device market also key product little burden surrounding blood vessel heading division entered market nobori stent toward scheduled start japan sale fiscal 2016 working ultimaster stent next product ultimaster subject marketing effort reflect another step forward taken fiscal 2013 toward expectation significant earnings developing latter granted ce mark enabling neurovascular division global expansion stent commencement european sale fiscal 2014 balloon product launched fiscal 2013 followed looking future terumo joined series market introduction new product currently development new type stenta drugeluting development taking place several year bioresorbable scaffold name implies introduction aimed maintaining high growth resorbed inside body eventually leaving foreign next priority undertake sweeping reform substance specific term entered joint improve profitability improvement profitability development agreement proprietary coating cost management important global trend technology used new bioresorbable scaffold price pressure farreaching improvement project achieve development arterial remodeling technology sa art competitiveness global market already moving forward france part agreement also obtained exclusive division mainstay ashitaka factory acquisition right art third list priority strengthening quality another area mediumto longterm growth management system production percentage expected endovascular intervention signed sale volume u market rise global basis joint development agreement kaneka corporation becoming important quality management japan related move also entered cooperation system comply latest fda standard cv agreement fmd co ltd another japanese company system division ann arbor factory meant radical facilitate access market therapeutic guidewires improvement response fda finding agreement expected open door hopeful effort pay fiscal 2014 broad range product significant step toward fourth priority evolution global management achieving competitive advantage field approach cardiac vascular company consists four endovascular intervention division global headquarters function fiscal 2013 also year important progress responsible operation also financial global production strategy first two important performance market outside japan accounting action moved forward strategic shift roughly 80 sale cardiac vascular company interventional device manufacturing expanded already operating condition business vietnam factory lightening burden mainstay competitiveness determined efficiency global ashitaka factory improving cost competitiveness operation therefore currently working globally second expanded production capacity strengthen company supply chain management factory costa rica opened fiscal 2012 cardiac vascular company strives remain abreast manufacture product highgrowth neurovascular global trend cuttingedge medical device division enhanced capability meet expanding provide solution offering new value continue investing global demand provide cost benefit internal development also actively pursuing strategic alliance opportunity order extend competitive advantage going forward drugeluting coronary artery stent ultimaster occlusion balloon scepter terumo corporation 20 annual report 2014 business overview cardiac vascular company cardiac vascular company contributes cuttingedge treatment including cardiac vascular surgery interventional procedure performed inside blood vessel pursuing therapy minimize physical burden patient interventional therapy performed tri blood vessel wrist coronary artery lesion tri reduce physical burden patient performing interventional therapy increasing number practitioner recent year adopted stent deployed approach gain blood vessel access site lesion wrist rather groin terumo offer device training specialized introduce interventional device approach via artery wrist providing comprehensive solution every step blood vessel access treatment type interventional device intravascular imaging system combined access device enables blood vessel access guide lesion intravascular imaging system used therapeutic device delivered system confirm intravascular condition use therapeutic device access device introducer sheath guidewires guiding catheter therapeutic device intravascular balloon catheter stent ofdi intravascular ultrasound system imaging system ivus terumo corporation 21 annual report 2014 optimizing cardiovascular surgery applying interventional technique approach cardiopulmonary bypass system perform therapy entire body cardiac vascular company provides artificial cardiac vascular company us technology coronary vascular graft used cardiovascular surgery intervention expand line product performing system temporarily perform function neurovascular intervention therapy peripheral intervention heart lung cardiovascular surgery lower extremity procedure improving performance device helping make surgery less physically stressful patient neurovascular intervention cardiopulmonary bypass system cerebral blood vessel coil made platinum stent used prevent cerebral arterial filter aneurysm rupturing oxygenator causing subarachnoid hemorrhage coronary intervention coronary blood vessel heartlung machine balloon stent used improve coronary blood flow directly opening holding coil used treat cerebral open coronary blood vessel aneurysm help maintain circulation blood become blocked gas exchange cardiovascular surgery buildup cholesterol substance peripheral intervention peripheral blood vessel balloon stent used drugeluting stent restore blood flow peripheral eg leg blood vessel become blocked oxygenator heartlung artificial thoracic integrated arterial machine vascular graft filter temporarily temporarily used replace substitute substitute disease portion lung oxygenate heart circulate blood vessel peripheral stent blood blood primary product business field basis entire terumo group please note product availability may differ region terumo corporation 22 annual report 2014 business overview general hospital company enhancing line highvalue added product improve safety efficiency medical setting improve profitability hiroshi matsumura president general hospital company fy 2013 result net sale business billion yen net sale business billion yen dm consumer general hospital net sale 1641 billion yen healthcare product asia others japan 241 147 809 493 172 105 1258 766 dd europe fy 2013 fy 2013 operating income 208 billion yen 223 136 1641 123 75 1641 pharmaceutical nutrition america operating profit margin 13 368 224 88 54 fiscal 2013 result making improvement earnings structure key issue going forward earnings structure improvement key issue fiscal 2013 sale increase general hospital key fiscal 2013 initiative company dd drug device division provides advancing area strategy diversifying prefilled syrinx pharmaceutical product added value enhanced combination drug market need medical device dm diabetes management mounting pressure control medical expense consumer healthcare division helped boost overall net developed country medical device manufacturer must sale 59 year year 1641 billion yen focus providing product deliver performance earnings however declined cause quality also contribute healthcare economics unfortunate development sale impact delay japan account half general hospital getting new product ground mainstay general company net sale need growing amid hospital product division developing business expanding market eldercare product service around infusion product effect lower contribute longterm care medicine contrast emerging productivity overseas factory operating margin market improving medical infrastructure operating income amortization depreciation generating growing demand medical device general divided net sale declined 15 year ago 13 responding diversifying need general hospital nanopass sale cumulative nanopass sale surpass 1 billion unit 6000 million yen fiscal 2005 fiscal 2012 nanopass nanopass 33g introduced 34g introduced 3000 15x million yen fiscal 2005 sale 200 million yen 2005 2006 2007 2008 2009 2010 2011 2012 2013 2016 fy terumo corporation 23 annual report 2014 company putting forth strategy tailored strategy going forward characteristic individual market achieve greater focusing improving profitability earningsyielding business performance expanding offering highvalueadded turning review main fiscal 2013 development business japan core general hospital product product division introduced new infusion syringe pump general hospital company work reduce production product data communication function cost mainstay product transform sale prefilled syrinx performed steadily highvalueadded business centered medical safety product sold directly hospital sold steadily implement strategy company adopt partnership pharmaceutical company together management approach integrates development pharmaceutical company partner terumo developing production sale emphasizes speed execution prefilled syrinx optimized ease use safety initial step company established administration stable storage delivery without impacting business structural improvement office restore profitability quality taking characteristic drug mainstay general hospital product pharmaceutical usage consideration specified customer nutrition division regard general hospital dm consumer healthcare division recorded product division particular transfer production higher sale blood glucose monitor painminimizing factory china philippine asian location nanopass 34g insulin injection needle expanded emphasize quality profitability meanwhile area cancer treatment growth strategy general hospital company postoperative pain management dd division launched enhancing offering new product group field acelio intravenous injection 1000mg first intravenous requiring highvalueadded product mainstay general injectable acetaminophen antipyretic analgesic enter hospital product division currently working boost japanese market working expand business productivity expand sale surflo v3 iv catheter acetaminophen available japan oral infusion therapy safety feature surplug ad series medication suppository child palliative closed infusion system infusion syringe pump data care however concluded acetaminophen communication function help ensure correct drug infusible form necessary terumo asked administration along new valueadded product ministry health labour welfare develop contribute efficiency accident prevention product expectation new intravenous medical setting product offered injectable acetaminophen permit appropriate pain individual component system bring greater overall management also oral administration suppository safety convenience medical setting reduce cost practical postoperative care use cancer patient effort made expand adoption overseas operation lowreturn business europe chemoshield anticancer drug administration system north america reviewed part business reduce risk oncology nurse come direct portfolio restructuring general hospital product exposure anticancer drug pharmaceutical division infusion pump intravenous needle led nutrition division attention focused strengthening sale increase asia central south america nutrition business includes new mermed regarding capital expenditure production line semisolid food product case gastroesophageal prefilled syrinx fujinomiya factory expanded reflux concern terumeal series caloriedense investment made boost production glucose food product oral consumption monitoring related product kofu factory dd drug device division growing market investment made building production segment working develop business continuing facility new yamaguchi factory work expand domestic market share proprietary product proceeding toward operational startup overseas investment accelerating global strategic alliance area pain made expand production syrinx factory management growth effort focused acelio philippine achieve lower cost maintaining quality intravenous injection 1000mg acetaminophen product discussed dm consumer healthcare division also growth driver striving boost market share hr joint line glucose body temperature blood pressure monitor equipped data communication function time working achieve greater adoption nanopass 34g needle surflo v3 iv catheter terumo corporation 24 annual report 2014 business overview general hospital company general hospital company strives improve safety ease use therapy device used hospital home enhancing safety drug administration infusion system infusion system used throughout hospital ward intensive care unit terumo develops infusion system offer greater safety helping ensure use right drug right amount reducing risk airborne contamination accidental needle stick systembased drugadministration safety infusion solution designed prevent infusion pump administration without proper installed drug library preparation infusion help prevent mistake flow solution bag rate infusion line connector iv catheter closed infusion system engineered prevent leak prevention airborne accidental needle stick contamination drug device dd combining drug medical device technology general hospital company provides product enable safe handling multiple drug even emergency medical setting prefilled syrinx prefillable syringe prefilling syrinx drug enhances terumo custom develops syrinx safety administration drug suit characteristic biopharmaceuticals drug used administer terumo corporation 25 annual report 2014 bringing greater efficiency daily care measuring device system nutritional supplement communication function general hospital company provides product optimized system centrally manages patient data required daily term nutritional content form palatability people treatment contributing efficient nursing care risk special nutritional need arising hospitalization management advanced age factor designed simplify preparation product also consider need caregiver condensed liquid meal condensed liquid meal blood glucose meter blood semisolid oral intake pressure monitor formulated viscosity water product come variety thermometer content level addressing flavor making appropriate communication functionality gastroesophageal reflux use entrée type enhances efficiency hydration need meal item management vital sign giving peace mind people battling cancer pain management closed anticancer drug infusion system general hospital company provides medication infusion system designed prevent direct contact supporting treatment cancer patient anticancer drug preparation administration terumo offer line allow pharmacist nurse involved provision pharmaceutical consisting chemotherapy perform job without fear exposure various analgesic including powerful drug opioids administered dosage anticancer drug infusion adjusted individual pain level system antiemetic suppress nausea system mitigates risk administration direct exposure anticancer anticancer drug addition drug every step drug product preparation administration offering wide assortment drug original generic also help lighten drug analgesic antiemetic cost patient primary product business field basis entire terumo group please note product availability may differ region terumo corporation 26 annual report 2014 business overview blood management company global leader proven financial track record history driving customer value enhancing patient outcome david perez president blood management company president ceo terumo bct inc fy 2013 result net sale business billion yen net sale business billion yen collection net sale 927 billion yen cell therapy etc blood component asia others japan 211 227 414 447 165 179 138 148 fy 2013 fy 2013 operating income 186 billion yen 927 927 whole blood collection europe america operating profit margin 20 302 326 256 276 368 397 component developed market due patient blood unlocking potential blood management initiative slower pace regulatory terumo bct global leader blood banking transfusion approval healthcare cost containment initiative medicine cellular therapy industry strong powerful market forceswe continued grow history innovation quality service combined strengthen business steadfast commitment 5000 associate proud announce business grew rate stakeholder customer 120 country patient outpaced competitor increased sale 241 ultimately serve yearonyear 927 billion yen increased twice rate sale growth increased cash flow fiscal 2013 result increased sale profit even fiscal 2013 key strategy challenging environment focused protecting extending market share fiscal 2013 set ambitious goal worked hard developed market expanding presence achieve even many challenge facing developing market achieving strong growth africa asia healthcare industryincluding reduced demand blood eastern europe latin america middle east blood management company net sale sustained profitable growth long term growth continues fiscal 2016 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99 01 03 05 07 09 11 13 15 fy net sale fiscal 2010 earlier total premerger sale terumo transfusion cardianbct actual foreign exchange rate used past year projected rate used fiscal 2014 terumo corporation 27 annual report 2014 leveraged product portfoliothe expand product portfolio one example new agreement comprehensive industryand diversified therakos inc serve exclusive distributor australia strategic alliance launch several new product new zealand six latin american county innovation pipeline customer developed developing country starting invest newly innovation leverage comprehensive portfolio introduced whole blood automation pathogen innovation pipeline reduction technology also grew therapeutic company built listening collaborating apheresis cell processing business worldwide global customer research product development innovation practice helped pave way continued strengthen manufacturing capability nextgeneration application future innovation increasing production capacity controlling cost fiscal 2014 innovation development budget providing excellent service customer worldwide increase approximately 18 addition increasing investment innovation taken measure improve process driving faster timetomarket strategy going forward better aligning new nextgeneration technology looking forward strong growing profitable market trend sale growth challenging given difficult market dynamic organization poised grow faster global manufacturing strategic strong overall market competitor within industry uniquely positioned deliver established strategy longterm sustainable profitable exceptional service customer across globe growth proven successful marketplace continue implement comprehensive global remain committed continue listen manufacturing strategy several key expansion designed customer deliver product meet need increase production enhance business continuity lower need blood donor patient serve cost new fdacertified facility opening vietnam expansion u india northern ireland underway market share protect extend expand ability manage cost good productivity continue protect extend market share efficiency never stronger developed market japan north america western europe expanding presence developing market diversification support expand eastern europe latin america middle east three established core businessesblood center southeast asia tiered approach help offset decreasing therapeutic apheresis cell processingour company demand blood created patient blood management brings wide range solution market initiative developed area opportunity continue focus supporting area optimistic sustainable profitable growth developing region rapid growth area cell processing based work increase adoption accessibility clinical progress validate use cell therapy treat therapeutic apheresis area neurology nephrology complex difficult widely prevalent disease like cancer hematology immunotherapy technology offer heart disease diabetes promise wide range disease also continue drive global adoption whole blood automation challenging time global economy pathogen reduction cell processing technology also exciting era organization potential wellestablished global infrastructure provides blood virtually unlimited potential terumo bct foundation business development activity foreign exchange rate neutral headquarters u state colorado vietnam factory completed july 2014 terumo corporation 28 annual report 2014 business overview blood management company offer system highquality efficient collection processing donated blood global basis furthermore expanding application apheresis system employ outstanding centrifugal separation technology providing patient new option treating various blood disease enabling highquality safe transfusion need blood transfusion people experienced significant loss blood wholeblood transfusion performed many type surgery treat victim serious accident people disease prevent people disease prevent body making enough blood production healthy blood disease patient become deficient disease leukemia thrombasthenia blood component diminished bone abnormality marrow function treated transfusion production blood component treated blood component blood therapy component collection whole blood collection device allows blood center contributes transfusion medicine safe efficient safely efficiently collect highquality collection processing donor blood needed blood component us single needle repeated draw return phase isolates main blood component continuous centrifugal separation technology making possible collect platelet plasma return red blood cell blood bag system leukocyte reduction filter automated blood collection system automated blood component processing system terumo corporation 29 annual report 2014 pathogen reduction technology inactivating pathogen residual white blood cell evade pathogen reduction detection blood product technology contributes greater technology system safety blood transfusion available sale japan providing new option treating intractable disease blood therapy cell expansion therapeutic apheresis technology functionally closed hollowfiber bioreactor technology enables broad range customizable streamlines cell expansion reproducible scalable procedure including therapeutic automated process specifically designed address space exchange depletion performed challenge labor demand associated cell therapy highlevel automation development system also reduces contamination risk doesnt sacrifice flexibility associated manual expansion control operator need achieve procedure outcome system also enable adaptable cell collection cell therapy high yield transplantation dos well cell processing technology monocyte enrichment versatile cell washing concentration therapeutic apheresis system cell expansion system primary product business field basis entire terumo group please note product availability may differ region terumo corporation 30 annual report 2014 financial information fiveyear financial summary consolidated 32 financial information 33 consolidated financial statement 38 terumo corporation 31 annual report 2014 fiveyear financial summary consolidated terumo corporation consolidated subsidiary fiscal year ended march 31 million yen fy 2009 fy 2010 note 3 fy 2011 fy 2012 fy 2013 fiscal year ended march 2010 ended march 2011 ended march 2012 ended march 2013 ended march 2014 net sale 316009 328214 386686 402294 467360 operating income 63282 62607 63049 53216 65289 income tax minority interest 63406 51560 49650 52285 52908 net income 40722 32339 24167 47014 34096 net cash provided used operating activity 67352 46829 56200 50270 96260 net cash provided used investing activity 25273 18989 247182 31294 52745 free cash flow 42079 27840 190982 18976 43515 net cash provided used financing activity 11488 26417 182982 22340 31786 research development expense 17528 20356 24322 27129 30130 capital expenditure 18440 21562 21132 25715 39933 depreciation amortization note 1 19909 20392 28835 32554 39881 per share indicator note 2 yen earnings per share eps 10722 8515 6364 12380 8978 dividend 3200 3400 3900 4400 5800 book value per share bps 83447 88266 92762 115221 130672 fiscal year million yen current asset 230432 236511 256868 286955 310986 current liability 99732 78846 157998 115844 160937 working capital 130700 157665 98870 171111 150049 total asset 425508 420038 692520 771032 832814 net asset 317140 335457 352537 437909 496245 capital 38716 38716 38716 38716 38716 management indicator roe 137 99 70 119 73 roa 101 76 43 64 43 shareholder equity ratio 745 798 509 567 596 share outstanding end fiscal year 189895 189881 189879 189878 189875 thousand employee end fiscal year 13740 14761 18112 18893 19263 note 1 including amortization goodwill 2 2for1 stock split carried terumo common share effective april 1 2014 information purpose figure net income per share net asset per share adjusted reflect would stock split carried beginning fiscal 2009 3 fiscal year end five asian consolidated subsidiary changed march 31 december 31 result fiscal 2010 company lasted total 15 month starting january 1 2010 ending march 31 2011 change fiscal year end effect increasing net sale 1923 million yen operating income 970 million yen ordinary income 916 million yen net income 685 million yen fiscal 2010 terumo corporation 32 annual report 2014 financial information net sale income net sale net sale japanoverseas compared previous fiscal year net sale increased billion yen 162 4674 billion yen 500 4674 amount net sale japan came 1891 billion 3867 4023 400 yen 17 yearonyear reflecting ongoing sale growth 3160 3282 2783 1962 2164 blood glucose monitoring system general hospital 300 1511 1421 company well improved result misago 200 peripheral stent new percutaneous transluminal 1771 1905 1859 1891 coronary angioplasty ptca dilation catheter cardiac 100 1739 vascular company business increased sale 0 2009 2010 2011 2012 2013 fy automated blood component collection system blood change fiscal yearends consolidated subsidiary march 31 december bag blood management company outside japan 31 order unify fiscal yearend consolidated group member added 1923 billion yen overseas net sale fiscal 2010 net sale jumped 286 2783 billion yen yearonyear driven increased sale automated blood component collection system business expansion emerging country blood management company strong operating incomeoperating income amortization goodwill intangiblesoperating profit margin performance business particularly america amortization goodwill intangible billion yen gross profit 120 25 206 gross profit totaled 2420 billion yen increase 177 196 196 100 166 175 20 compared previous fiscal year improved profit due 80 760 816 633 650 626 642 630 668 653 depreciating yen expanded lineup highly 15 60 532 profitable product cardiac vascular company 10 blood management company offset delay ramping 40 sale new product general hospital company 20 5 yielding overall growth 0 2009 2010 2011 2012 2013 fy 0 operating income goodwill intangible refers goodwill marelated intangible asset arising acquisition cardian bct excludes reveosrelated rd asset definition set forth segment information fiscal 2013 earnings report operating income jumped 227 yearonyear 653 billion yen despite increase rd expense general administrative expense included investment intended foster business growth operating income net incomeroe billion yen grew result higher sale gross profit 75 137 15 benefit depreciating yen 119 60 12 99 net income 470 45 407 73 9 net income decreased 275 yearonyear 341 billion 70 323 341 yen decrease mainly due impairment loss 30 242 6 noncurrent asset resulting nonprofitable business 15 3 facility despite extraordinary income 60 billion yen settlement received 0 2009 2010 2011 2012 2013 fy 0 terumo corporation 33 annual report 2014 financial information result business segment cardiac vascular company fiscal 2013 net sale business segment japan cardiac vascular company boosted sale expanding product range individual therapeutic cardiac vascular company billion yen field example included misago peripheral stent neuro cv vascular total vascular system graft hiryu plus ptca dilation catheter interventional system japan 362 20 92 21 495 outside japan business continued generate america 370 54 213 17 654 strong result tri grew popularity north america europe 411 54 56 69 590 neurovascular business sale new product asia stent expanded globally others 270 46 43 08 367 result activity cardiac vascular total 1413 174 404 115 2106 company recorded 241 yearonyear increase net sale 2106 billion yen general hospital company general hospital company billion yen japan delay ramping sale newly released pharma general dm ceutical infusion systemsrelated product negative impact hospital dd consumer total product healthcare nutrition sale profit sale prefilled syrinx product japan 504 368 177 209 1258 related blood glucose monitoring system continued america 79 08 01 88 grow driving overall sale 13 yearonyear outside europe 78 37 08 123 japan sale expanded country asia result asia factor net sale general hospital company others 148 00 01 23 172 rose 59 compared previous fiscal year reaching total 809 368 223 241 1641 1641 billion yen blood management company competition intensified japan sale product blood management company billion yen whole blood collection automated blood collection cell whole blood blood therapy total component collection system increased driving component collection etc overall sale 73 yearonyear outside japan patient japan 60 69 09 138 blood management program negatively impacted america 203 58 107 368 demand europe united state sale new europe 87 99 70 256 automated blood component processing system still asia 64 76 25 165 others managed expand europe sale automated blood component collection system continued grow total 414 302 211 927 emerging country owing factor net sale blood management company rose 241 yearonyear 927 billion yen terumo corporation 34 annual report 2014 balance sheet cash flow information total asset total assetsroa total asset rose 618 billion yen 8328 billion yen billion yen primary factor behind increase included acquisition 1000 15 property plant equipment increase 8328 7710 800 market valuation investment security exchange 101 6925 10 rate impact 600 76 4255 4200 64 liability 400 43 5 43 liability increased 34 billion yen 3366 billion yen 200 change due primarily 158 billion yen increase income tax payable 0 2009 2010 2011 2012 2013 fy 0 total net asset total net assetsshareholders equity ratio net asset increased 583 billion yen 4962 billion yen billion yen 4962 contributing change 244 billion yen increase 500 100 4379 retained earnings 38 billion yen increase valuation 798 745 400 3525 80 difference availableforsale security foreign 3171 3355 exchange impact 567 596 300 509 60 net cash provided used operating activity 200 40 net cash provided operating activity came 963 100 20 billion yen compared 503 billion yen provided fiscal 2012 income income tax totaled 529 billion yen 0 2009 2010 2011 2012 2013 fy 0 depreciation amortization 303 billion yen amortization goodwill 96 billion yen income tax paid 29 net cash provided operating activity billion yen billion yen 100 963 net cash provided used investing activity 80 net cash used investing activity came 527 billion yen 674 compared 313 billion yen used fiscal 2012 outlay 60 562 468 503 399 billion yen property plant equipment primary factor contributing result 40 20 net cash provided used financing activity net cash used financing activity came 318 billion yen 0 2009 2010 2011 2012 2013 fy compared 223 billion yen used fiscal 2012 180 billion yen net decrease shortterm loan payable cash flow billion yen primary factor contributing result fiscal 2012 fiscal 2013 change net cash provided used 503 963 460 operating activity net cash provided used reflecting result discussed cash cash investing activity 313 527 214 equivalent end fiscal year increased net cash provided used 223 318 95 financing activity 173 billion yen end prior fiscal year 925 cash cash equivalent billion yen consolidated basis year end 752 925 173 terumo corporation 35 annual report 2014 financial information rd activity cardiac vascular company commenced sale rd expense glidesheath slender sheath tri united state billion yen along flowdiverting stent occlusion balloon 40 neurovascular intervention market japan 301 europe company also obtained ce mark certification 30 271 243 ultimaster drugeluting stent february 2014 204 began sale europe june 2014 20 175 aim expanding future product pipeline company secured exclusive acquisition right 10 arterial remodeling technology sa french company developing bioresorbable stent concluded 0 2009 2010 2011 2012 2013 fy agreement pursue joint development series investment terumo also investing emergent medical partner ii lp u venture capital fund effort rd expense business segment gain latest technological expertise company blood management cardiac company vascular company transferred development project incubator 63 billion yen 160 billion yen center started initiative achieving rapid commercialization result activity fiscal 2013 rd 289 billion yen expense came 301 billion yen 64 net sale general hospital company 66 billion yen cardiac vascular company company rd work consists research total rd expense fiscal 2013 include 12 billion yen basic research conducted rd headquarters cannot reasonably apportioned various company development interventional system cv product led terumos rd headquarters terumo cardiovascular system corporation research development launch status fiscal 2013 pipeline product neurovascular product led microvention inc field product region cardiac vascular company rd expense totaled peripheral stent knee japan 160 billion yen fiscal year coil assist stent china neurovascular flow diversion stent europe general hospital company occlusion balloon japan led terumos rd headquarters research new ptca balloon japan development work performed product coronary ofdi intravascular imaging system japan infusion device infusion fluid prefilled syrinx digital slenderized introducer sheath tri u thermometer digital blood pressure monitor renal sympathetic denervation system rsd europe ablation general hospital company rd expense totaled rsd tri technique europe 66 billion yen fiscal year automated blood component processing europe system prp method automated blood component processing europe blood management company blood system bc method management rd work company consists research data management system europe tacsi application development performed primarily terumos rd therapeutic apheresis system japan headquarters terumo bct holding corporation bone marrow stem cell application transfusionrelated product needless system japan blood management company rd expense infusion system safety iv catheter u asia totaled 63 billion yen fiscal year smart pump infusion syringe pump europe terumo corporation 36 annual report 2014 business risk following risk factor could negatively impact terumos risk associated overseas operation operating result financial position terumo supply product 160 country possible market terumo serf recession change government healthcare policy resulting contraction demand unanticipated healthcare industry government japan political instability sudden imposition government overseas continue restrain healthcare cost regulation country could impact company implement reform intended raise quality operating result financial position healthcare large unforeseen change government healthcare policy terumo cannot respond could quality control affect company operating result financial position terumo manufacture product based stringent quality control principle accordance market price fluctuation good manufacturing practice gmp standard part measure restrain healthcare cost japan pharmaceutical medical equipment iso japanese government enacts biennial revision quality management system standard government reimbursement drug medical treatment however conceivable quality medical equipment covered national health product could questioned complication occur insurance scheme addition intense competition use product addition even case innovation technology japan overseas medical accident clearly could direct could serve greatly lower price adversely affect result company product taking preventive company operating result financial position measure countermeasure mitigate possible occurrence risk product future raw material price fluctuation occurrence could lead decrease sale rise many raw material terumo us product cost could affect company operating result manufacture plastic material derived financial position petrochemical steep rise price resource worldwide could increase price raw material legal proceeding adversely affect company operating result terumo face risk involved lawsuit dispute financial position type legal proceeding japan overseas company strives minimize legal risk exchange rate fluctuation measure continuous research effort terumos headquarters located japan part legal intellectual property financial account overseas subsidiary converted department system internal check report local currency japanese yen preparation risk management structure provided board consolidated financial statement purpose director audit supervisory board needed exchange rate fluctuation therefore influence however company sued third party conversion account yen result either damage injunction sale major gain loss company legal action taken could affect company coping fluctuation structural operating result financial position method transferring production overseas factory importing raw material along risk utilization contract hedge exchange rate factor could impact terumos operating result volatility trade receivables financial position include change trade practice however possible unexpected exchange rate terrorism war natural disaster epidemic fluctuation could impact company operating result worldwide spread new strain influenza financial position terumo corporation 37 annual report 2014 consolidated financial statement consolidated balance sheet terumo corporation consolidated subsidiary fiscal 2013 fiscal 2012 million yen million yen fy 2013 fy 2012 fy 2013 fy 2012 asset march 31 2014 march 31 2013 liability net asset march 31 2014 march 31 2013 current asset current liability shortterm debt 260 18046 cash deposit 95619 78201 current portion longterm 4652 3762 debt note account 101520 95008 current portion bond 40000 receivabletrade payable less allowance doubtful note account payable 1394 1220 trade 38148 37515 account lease obligation 226 277 note account receivabletrade net 100126 93788 income tax payable 18402 2609 accrued expense 30934 25802 inventory 93966 85180 asset retirement obligation 420 deferred tax asset 12341 11258 current liability 28315 27413 total current liability 160937 115844 current asset 8934 18528 total current asset 310986 286955 noncurrent liability bond payable 40000 80000 longterm debt 76770 78712 property plant equipment lease obligation 299 439 land 21758 21827 provision retirement benefit 1248 retirement benefit liability 3125 building structure 148177 136828 provision director 67 199 machinery equipment retirement benefit 209614 197713 asset retirement obligation 220 156 vehicle deferred tax liability 47796 49659 lease asset 1590 1611 noncurrent liability 7355 6866 construction progress 27975 17794 total noncurrent liability 175632 217279 equipment furniture 40355 38504 total liability 336569 333123 449469 414277 net asset capital stock less accumulated depreciation 291714 269452 authorized 840000000 share fy2013 fy2012 net property plant issued 189880260 share equipment 157755 144825 38716 38716 fy2013 fy2012 capital surplus 52104 52104 investment asset retained earnings 353601 329189 less treasury stock cost 24 9 investment security including investment total shareholder equity 444397 420000 security unconsolidated 37955 30305 valuation difference availableforsale security 11270 7458 subsidiary affiliate deferred gain loss goodwill 154161 149322 hedge 2 customer relationship 93969 90707 foreign currency translation adjustment 43377 10099 deferred tax asset 5323 5154 accumulated adjustment 2817 retirement benefit retirement benefit asset 2573 total accumulated comprehensive income 51828 17557 asset 70092 63764 stock subscription right 20 total investment minority interest 352 asset 364073 339252 total net asset 496245 437909 total asset 832814 771032 total liability net asset 832814 771032 terumo corporation 38 annual report 2014 consolidated statement income terumo corporation consolidated subsidiary fiscal 2013 fiscal 2012 million yen fy 2013 fy 2012 ended march 31 2014 ended march 31 2013 net sale 467360 402294 cost sale 225348 196606 gross profit 242012 205688 selling general administrative expense 176723 152472 operating income 65289 53216 income expense interest dividend income 799 592 royalty income 117 124 foreign exchange gain 3250 1258 equity earnings affiliate 133 177 gain sale property plant equipment 743 78 gain transfer business 667 892 settlement income 6000 subsidy income 876 interest expense 1543 1304 loss disposal inventory 837 678 loss disposal property plant equipment 995 543 impairment loss 15351 director retirement benefit 33 loss liquidation business 740 loss information system failure 1186 loss valuation golf club membership 3 environmental expense 391 net 3405 2009 12381 931 income income tax minority interest 52908 52285 income tax current 26637 7179 deferred 7856 1961 18781 5218 income minority interest 34127 47067 minority interest income 31 53 net income 34096 47014 yen net income per common stock basic 8978 12380 diluted 8978 terumo corporation executed twoforone stock split common share effective april 1 2014 net income per common stock adjusted retrospectively reflect effect stock split cash dividend per common stock 5800 4400 terumo corporation 39 annual report 2014 consolidated financial statement consolidated statement comprehensive income terumo corporation consolidated subsidiary fiscal 2013 fiscal 2012 million yen fy 2013 fy 2012 march 31 2014 march 31 2013 income minority interest 34127 47067 comprehensive income valuation difference availableforsale security 3811 7510 deferred gain loss hedge 2 2 foreign currency translation adjustment 33234 39157 share comprehensive income associate accounted using equity method 3 3 total comprehensive income 37040 46668 comprehensive income 71167 93735 attributable shareholder terumo corporation 71180 93648 minority interest 13 87 consolidated statement change net asset terumo corporation consolidated subsidiary fiscal 2013 fiscal 2012 thousand million yen shareholder equity accumulated comprehensive income valuation number difference deferred foreign accumulated stock share capital capital retained treasury gain currency adjustment minority loss translation retirement subscription total capital stock surplus earnings stock available interest right stock forsale hedge adjustment benefit security balance march 31 2012 189879 38716 52104 290529 4 52 2 29023 265 352537 dividend surplus 8354 8354 net income 47014 47014 purchase treasury stock 1 5 5 net change item 7510 2 39122 87 46717 shareholder equity balance march 31 2013 189878 38716 52104 329189 9 7458 10099 352 437909 dividend surplus 9684 9684 net income 34096 34096 purchase treasury stock 3 15 15 net change item 3812 2 33278 2817 20 352 33939 shareholder equity balance march 31 2014 189875 38716 52104 353601 24 11270 2 43377 2817 20 496245 terumo corporation 40 annual report 2014 consolidated statement cash flow terumo corporation consolidated subsidiary fiscal 2013 fiscal 2012 million yen fy 2013 ended march 31 2014 fy 2012 ended march 31 2013 net cash provided used operating activity income income tax minority interest 52908 52285 depreciation amortization 30322 24603 impairment loss 15351 amortization goodwill 9559 7952 equity earnings affiliate 133 177 increase decrease provision retirement benefit 1248 535 decrease increase retirement benefit asset 1900 increase decrease retirement benefit liability 1506 increase decrease provision director retirement benefit 132 3 increase decrease allowance doubtful account 73 96 increase decrease provision director bonus 1 18 interest dividend income 799 592 interest expense 1543 1304 foreign exchange gain 3211 2977 gain transfer business 667 892 settlement income 6000 gain sale property plant equipment 743 78 loss disposal property plant equipment 995 543 payment cash contribution retirement benefit trust 3600 director retirement benefit 33 loss liquidation business 740 loss information system failure 1186 loss valuation golf club membership 3 subsidy income 876 environmental expense 391 decrease increase note account receivabletrade 507 986 decrease increase inventory 3619 10590 increase decrease note account payabletrade 1096 3925 net 4850 79 subtotal 95412 75079 interest dividend income received 1020 842 interest expense paid 1522 1330 income tax paid 2876 24322 settlement received 6000 payment director retirement benefit 33 payment information system failure 943 payment environmental expense 798 subsidy received 1 net cash provided operating activity 96260 50270 net cash provided used investing activity payment time deposit 767 561 proceeds withdrawal time deposit 1183 2803 purchase property plant equipment 39933 25715 proceeds sale property plant equipment 953 322 purchase intangible asset 4961 6759 payment settlement asset retirement obligation 420 420 purchase investment security 1824 1074 payment acquisition business 1828 purchase investment subsidiary resulting change scope consolidation 374 956 purchase stock subsidiary 1519 proceeds transfer business 1815 1373 net 5070 307 net cash used investing activity 52745 31294 net cash provided used financing activity proceeds shortterm debt 253 1264 repayment shortterm debt 49 1279 repayment longterm debt 4007 net increase decrease shortterm debt 18000 42000 proceeds longterm debt 28613 repayment finance lease obligation 284 579 purchase treasury stock 15 5 cash dividend paid 9684 8354 net cash used financing activity 31786 22340 effect exchange rate change cash cash equivalent 5603 4736 net increase cash cash equivalent 17332 1372 cash cash equivalent beginning year 75166 73794 cash cash equivalent end year 92498 75166 terumo corporation 41 annual report 2014 corporate governance corporate governance policy 43 compliance 52 terumo corporation 42 annual report 2014 corporate governance policy basic stance accordance corporate mission contributing society healthcare terumo corporation responds expectation customer shareholder associate business partner community large stakeholder worldwide providing valuable product service achieve sustainable growth maximize corporate value long term terumo set forth corporate mission five statement open management enhanced value safety reliability respect associate corporate citizenship statement govern action decision made terumo associate backed corporate mission five statement terumo promotes creation framework honest effective corporate governance together commitment full accountability action terumo strives continuously earn understanding trust within outside company terumo belief corporate culture create highly motivating challenging workplace open candid communication forward looking spirit essential effective corporate governance strives diligently foster culture kind terumo employee called associate emphasize partnership collaborative working corporate governance structure governance terumo based company board company auditor system defined japan company act business activity supervised board director audit supervisory board entrusted auditing function established corporate governance committee internal control committee enhance objectivity transparency management decisionmaking strengthen oversight business activity dedicated staff assigned support audit function strengthen governance way well believe step continuously increase corporate value maintain highly transparent governance system operation terumo corporation 43 annual report 2014 based corporate governance policy established board director board may 15 director 20 may independent director audit supervisory board may five member least half must external member independent director external audit supervisory board member must meet tokyo stock exchange requirement concerning independent director external auditor independent directorauditor notification appointment submitted tokyo stock exchange independent director external member audit supervisory board except one notification submitted accordance rule firm serf corporate governance structure board director board director presently consists 13 member three independent director two director one internal one independent woman one internal outside japan elected 99th annual general meeting shareholder convened june 24 2014 addition legally prescribed body detailed company established body described view enhancing corporate governance terumo corporation 44 annual report 2014 director board director 1 role board director decides matter authorized relevant law regulation article incorporation internal rule monitor performance duty individual director executive officer strives optimal management decisionmaking view maximizing corporate value fulfills corporate governance function 2 composition board director consists 15 director 20 may independent director independent director must satisfy criterion serve independent directorsauditors defined tokyo stock exchange board director chaired chairman representative director terumo 3 term office director term office director one year reappointment possible corporate governance committee internal control committee company also established corporate governance committee internal control committee body serve enhance transparency objectivity management half member corporate governance committee independent director independent director chair committee corporate governance committee advisory body deliberates advises selection candidate director audit supervisory board member executive officer remuneration system audit supervisory board member executive officer internal control committee work enhance corporate governance promoting risk management compliance regard management administering timely appropriate disclosure corporate information terumo corporation 45 annual report 2014 corporate governance committee 1 role deliberates advises following matter order heighten fairness board director management transparency corporate governance structure enhancement selection candidate position director audit supervisory board member executive officer establishment remuneration system director audit supervisory board member executive officer 2 composition comprised maximum six member drawn independent director representative director individual named committee chair half membership must independent director satisfy criterion serving independent directorsauditors defined tokyo stock exchange 3 committee chair chair corporate governance committee selected among independent director mutual vote committee member internal control committee 1 role promotes risk management compliance respect management administers legally mandated timely disclosure corporate information 2 composition comprised director appointed committee chair general manager relevant division well head specialized group internal audit department internal control department audit supervisory board member attend internal control committee meeting 3 committee chair internal control committee chaired president representative director company terumo corporation 46 annual report 2014 audit supervisory board audit supervisory board comprised four member two external member determines governance practice place practice place work ensure propriety daily management activity including board director function audit supervisory board member monitor performance duty director example attending board director executive management important meeting may state fair impartial opinion management generally particular matter enhance audit function audit supervisory board office established staffed fulltime personnel support organization audit supervisory board member audit supervisory board member hold monthly report meeting internal audit department receive report internal audit financial reporting internal control undertake activity aimed ensuring strong relationship internal audit department audit supervisory board member also attend internal control committee meeting receive regular report establishment implementation evaluation internal control regarding cooperation independent auditor audit supervisory board member meet approximately six time annually independent auditor actively sharing view information receive report ongoing audit needed audit supervisory board member also perform activity receiving report needed financial reporting internal control ensure system enabling performance fair audit place audit supervisory board member audit supervisory board 1 role audit supervisory board member audit supervisory board audit supervisory board member attend meeting board director important meeting audit execution duty director offer pointed input regarding management required audit supervisory board responsible following preparation audit report election dismissal fulltime audit supervisory board member determining audit policy method assessing status company operation financial asset matter pertaining duty performed audit supervisory board member terumo corporation 47 annual report 2014 2 composition consists five audit supervisory board member half must external audit supervisory board member external audit supervisory board member must meet term stipulated japan company act satisfy criterion serve independent directorsauditors defined tokyo stock exchange chair audit supervisory board elected resolution among audit supervisory board member 3 term office term office audit supervisory board member four year reappointment possible internal control accordance japan company act terumo corporation board director approved internal control system basic policy given internal control committee take lead promoting establishment internal control system within terumo group internal control system basic policy 1 system ensuring execution duty director employee consistent relevant law ordinance article incorporation ① step taken ensure thorough compliance code conduct terumo group confirm every director employee group understands code conduct terumo group addition education enlightenment activity conducted ongoing basis foster sense ethic enhance compliance awareness among employee ② internal control committee deliberates compliance important matter report result regular basis board director ③ internal audit department audit group status regard compliance regularly report result representative director audit supervisory board ④ use internal whistleblowing system promoted uncover activity legally questionable 2 system retaining managing information performance duty director ① accordance documentation management standard information performance duty director recorded paper electronic form referred documentation retained ② system maintained allows director audit supervisory board member view terumo corporation 48 annual report 2014 document time 3 rule systematic approach management risk ① regarding individual quality compliance disaster environmental information security type individual risk expert unit risk category educate guide employee ongoing basis accordance relevant rule provision ② internal control committee deliberates important risk management matter work expert unit compliance officer group company establish risk management system span breadth optimal terumo group internal control department work advance system 4 system ensuring efficiency performance duty director executive management committee company committee market product strategy committee committee consisting director executive officer others member make decision toward achievement mediumterm management annual plan approved board director enhance terumo group corporate value promote shareholder common interest promote efficiency speed expert committee provide support guidance oversight business unit 5 system ensuring proper operation corporate group consisting company parent company subsidiary ① regarding terumo group internal control committee working close cooperation head terumo corporation unit compliance officer group company reinforce system swift efficient communication instruction report relating propriety group operation internal control department work advance action taken internal control committee ② internal audit department conduct internal audit group regularly report result representative director audit supervisory board 6 matter related employee assigned assist audit supervisory board member performance duty independence assigned employee director audit supervisory board office dedicated staff support performance audit work audit supervisory board member evaluation transfer staff require consent audit supervisory board 7 system reporting audit supervisory board member director employee system reporting audit supervisory board member ① director employee may submit report audit supervisory board member necessary based legal provision separately provided internal rule governing reporting matter director employee audit supervisory board member ② deemed necessary audit supervisory board member audit supervisory board member may receive report needed director employee 8 terumo corporation 49 annual report 2014 system ensuring auditing audit supervisory board member conducted effectively ① audit supervisory board representative director regularly hold meeting share opinion ② audit supervisory board member may attend executive management important meeting ③ audit supervisory board hold monthly meeting internal audit department meet regularly independent auditor meet internal audit department independent auditor time necessary executive compensation compensation director independent director consists fixed portion bonus stock option compensation independent director audit supervisory board member consists fixed amount process determining compensation described table compensation director audit supervisory board member related matter disclosed within asset security report business report posted terumo corporation website process determining compensation director audit supervisory board member category determination process fixed within compensation limit approved 66th annual general meeting shareholder compensation director compensation decided resolution board director audit supervisory board member compensation decided audit supervisory board meeting bonus light factor year business result business environment bonus amount proposed annual general meeting shareholder submitted board director approval stock option decision stock option made board director resolution within compensation limit mentioned standard payment fixed compensation excluding audit supervisory board member bonus stock option considered corporate governance committee light information including provided outside research organization comparable standard used company terumo corporation 50 annual report 2014 timely disclosure information terumo aim company trusted throughout society emphasizing transparency fairness continuity make information disclosure shareholder investor customer stakeholder required financial instrument exchange act tokyo stock exchange timely disclosure rule also engage timely proactive disclosure information believe effective enhancing understanding company system timely disclosure line corporate governance policy established disclosure subcommittee determine proposed disclosure handled positioned internal control committee disclosure committee make decision based consideration necessity disclosure timing matter legality propriety concerning documentation proposed disclosure disclosure subcommittee 1 subcommittee structure disclosure subcommittee composed head public relation corporate planning secretarial internal control department head public relation department chair subcommittee convenes meeting necessary chair determines necessary people subcommittee member may also asked attend public relation department act administrative section subcommittee performing disclosure procedure taking archiving meeting minute 2 subcommittee role disclosure procedure head unit responsible management subsidiary together referred responsible manager information resulted business activity could become subject disclosure agenda item board director executive management meeting internal control committee together referred committee scheduled meet information submitted disclosure subcommittee disclosure subcommittee considers necessity disclosure timing matter legality propriety concerning information proposed disclosure instructs responsible manager subcommittee administrative section necessary action committee scheduled meet deliberates agenda render final decision disclosure terumo corporation 51 annual report 2014 compliance compliance system terumos corporate mission contributing society healthcare goal company associate work terumo continue conduct honest fair business practice based strict legal compliance corporate ethic order maintain position ethical healthcare company promote honest fair business practice terumos board director approved basic policy internal control system accordance basic policy established internal control committee deliberates executes important groupwide compliance issue addition based direction internal control committee group company appointed compliance officer whose role facilitate carry compliance activity company activity internal control committee receives discusses important information enhance groupwide compliance activity compliance code conduct terumo group go toward meeting social expectation established code conduct terumo group april 2008 set standard conduct daily business activity entire group including overseas entity accordance code striving throughout terumo group base action social ethic well compliance relevant law regulation code conduct terumo group based terumos corporate mission heart terumo state associate must conduct business activity honestly take responsible action environmental conservation make consistent effort enable company become model reliable corporate citizen carry training code conduct tailored site encourage associate recognize importance corporate ethic global company also clearly state promote need respect human right eliminate discrimination code conduct terumo corporation 52 annual report 2014 appropriate relationship public official terumo associate observe code conduct terumo group terumo group global antibribery policy established may 2013 dealing public institution related official employee public medical institution code aim ensure business conducted fair transparent sound honest manner full compliance expected japan unfair competition prevention act u foreign corrupt practice act antibribery law within country region terumo group operates combatting antisocial force avoiding relationship antisocial force one terumos corporate responsibility therefore strictly refuse become involved relationship antisocial force engage transaction company organization individual tie antisocial force furthermore work law enforcement authority agency combat antisocial force status effort combat antisocial force general affair department coordinate response inappropriate demand antisocial force prevention inappropriate demand made specific responsibility designated associate within general affair department established system cooperating law enforcement authority tokubouren npo assisting company combatting corporate blackmailer legal adviser others acting advice guidance established system properly receiving information antisocial force tokubouren source centrally managing general affair department prepared manual combatting antisocial force promoting thorough understanding content among everyone working terumo provide executive associate relevant information timely manner conduct training take ther step well promote awareness importance combatting antisocial force terumo corporation 53 annual report 2014 corporate ethic hotline established corporate ethic hotline internal whistleblowing system 2003 corporate ethic hotline enables associate report consult matter situation believe inappropriate light code conduct terumo group system enables associate regardless employment status contact hotline phone email written letter anonymous basis time maintain outside point contact office corporate attorney way whistleblower assured privacy protection retaliation promote hotlines usage address reported issue corporate ethic hotline work terumo corporation 54 annual report 2014 abiding industry rule terumo abides code practice promotion code fair competition code industrybased rule ensure follows appropriate promotion practice medical device pharmaceutical effort fulfill social responsibility engage ethical business activity also established terumo code practice compliance industry internal rule remain top priority going forward terumo corporation 55 annual report 2014 intellectual property global rd system 57 utilization intellectual property business segment 65 patent 72 measure counterfeit product 75 global production system 76 quality management factory 78 terumo corporation 56 annual report 2014 global rd system present global medical device market undergoing seismic shift aging japan society continues industrialization healthcare nursing care led flood new entrant different business sector hand emerging country seeing rapid growth medical device market development healthcare infrastructure progress step economic advancement moreover western country demanding medical device product system offering even higher medical cost efficiency given curtailment medical expense key priority market landscape becomes increasingly complex way terumo working develop introduce new product according regional market need aim growing enterprise strong presence global stage terumo group rd base terumo corporation 57 annual report 2014 boosting development since 2000 terumo actively acquiring company technology establishing subsidiary worldwide basis obtaining technology strengthening product line capturing market share important objective undertaking activity another key interest however creation synergy combining fundamental technology long strength company give rise new value technological innovation fiscal year ended march 31 2012 example acquired usbased harvest technology corporation company outstanding technological capability cuttingedge medicine notably device harvesting various cell used stimulate surgical wound healing used cellular therapy january 2012 acquired technology usbased onset medical corporation adding unique large internal diameter sheath product line solidified terumos leading position area vascular access management enhancing development capability terumo corporation 58 annual report 2014 realize synergy overseas subsidiary terumo recent year actively assigned engineer japan foreign subsidiary encourage codevelopment local engineer moreover order respond healthcare regulation country group company collaborate one another pta balloon catheter headquarters function terumo business division placed overseas mean terumo created structure enables faster global promotion new product also collaborating actively company april 2013 instance signed agreement kaneka corporation expand peripheralinterventional business codevelopment pta percutaneous transluminal angioplasty balloon catheter use treating peripheral lower extremity artery disease march 2014 entered agreement arterial remodeling technology sa art france acquire exclusive acquisition right company developing bioresorbable stent technology agreement also pursue joint development drugeluting bioresorbable stent make staged investment art actively collaborating company invest development activity expanding market serve beyond existing field business new rd system based globalized businessled management anticipating impending shift companyled global management approach april 2014 reorganized rd two group july 2013 one company rd group charge developing product pipeline consistent business strategy nine business responsible integrated management everything product development production sale particular area based management strategy three company group corporate rd led rd headquarters corporate rd pursues rd aimed terumo corporation 59 annual report 2014 coming nextgeneration product existing business creating new business existing company also performs function developing terumos competitively superior basic technology performs evaluation function acquiring efficacy safety data required submitting regulatory application strengthen terumos overall rd capability corporate rd engages human resource development work create new development approach new rd system based globalized businessled management terumo corporation 60 annual report 2014 rd headquartersgiving rise innovation corporate rds mission create new value accurately assessing need medical setting advance new development activity focused early commercialization created development system spanning everything early stage development commercialization along two axesinternal development external development activitiesand conduct broad search effort create future product portfolio internal development advance new search activity specified field employing project team member including engineer also associate broad range function outside expert strives speedy commercialization clear target process new development external development activity take place global basis silicon valley prime example october 2013 committed invest emergent medical partner ⅱ emp ii venture capital fund managed dr thomas fogarty prominent cardiac surgeon inventor key aim investment gain early access technology developed highly promising venture business time established terumo medical innovation inc transferred fogarty institute innovation incubator operated dr fogarty inhouse development aim achieve clearly defined product objective speedy commercialization pursuing discovery defined area need search medical setting project team composed engineer also associate outside expert across wide range functional ax terumo corporation 61 annual report 2014 emergent medical partner dr thomas j fogarty right empⅱ office silicon fii ceo m ann fyfe valley upgrading improving sharing fundamental technology technology increase biocompatibility one example essential technology commonly required development manufacture medical device kind biocompatibility technology improved daily basis shared throughout terumo group medical device used diagnostic treatment purpose accessing patient body many different way medical device make contact surface patient body others inserted within body implanted body extended period time reason key priority access patient body safely minimizing undesirable physical burden patient enhancing biocompatibility product developing material inhibit allergic reaction blood clotting response making structural enhancement one factor distinguishes product outstanding medical device furthermore material used medical device must offer various characteristic light resistance deformity resistance sterilization resistance pharmacological compatibility according application terumos wealth experience technology material field put good use entire process development selection appropriate material processing forming shape reflect userfriendliness consideration performance processing molding sterilization production operation material terumo applies efficient rigorous quality assurance system based technology expertise production technology underpinned many year proven experience addition terumo factory amasses production technology related product manufacture taking part crossfactory system assist production factory ensures highquality production system factory terumo corporation 62 annual report 2014 organizational capability link translating technology product medical device represent integration extremely diverse range elemental technology host scientific discipline including physiology biochemistry pharmacology cell technology polymer technology metal processing technology electronics use within human body regulatory authority japan elsewhere set bar safety exceptionally high approving manufacture sale device discussed earlier terumo group variety elemental technology bulk human resource possess highly sophisticated expertise however stay ahead basic flow chart development sale medical device industry made fiercely competitive new entrant outside industry deliver new product society rapid steady pace company must organization framework capable integrating existing inhouse elemental technology concrete product development controlling flow linking product sale dealing rigorous approval process specific medical device achieve terumos rd headquarters strengthening project management function expediting research commercialization twopronged structure consists group responsible seeking new medical need underdeveloped technology draw new value charged developing product mass production base underpinning structure located rd center key terumo factory configuration establishes environment entire process initial rd stage new product mass production stage occur unimpeded part structure terumos evaluation center capacity evaluate device along physical chemical biological dimension evaluation center gather experimental terumo corporation 63 annual report 2014 data rd headquarters factory need rd activity enabling nonclinical study precede clinical trial performed inhouse capacity added merit enabling terumo acquire expertise performing safety evaluation responding diverse range technology addition numerous department functionally interlinked early stage development allowing efficient conversion rd activity viable product department include coordinate clinical trial responsible submitting application compliance foreign domestic regulatory affair law negotiating approval body research oversee postmarket product effectiveness safety matter intellectual property department charged research protection intellectual property right recent year terumo promoted strategic collaboration overseas subsidiary leveraging competitive edge multiple development base overseas swiftly incorporate technology develop new product example terumo conducted clinical trial based european union regulation trial implemented speedily japan also performed simultaneous multinational clinical trial close collaboration subsidiary trial aimed obtaining early approval enabling approval body country share data obtained respective country terumo honed organizational frameworkone smoothly support process product development salesin course business activity long history medical device company result initiative proactive ma business alliance leading company around world recent year framework make vital part intellectual asset support terumos strength terumo corporation 64 annual report 2014 utilization intellectual property business segment basic policy terumo currently operates three core business segment exploring new field expected drive future business development business segment unique characteristic based difference product intended user attribute accordingly terumo plan promotes optimal business development initiative business segment combining proper material production technology regulatory affair strategy product management company comprised two componentsadvanced product platform product advanced product innovative highgrowthhighmargin shortlife cycle platform product stablegrowthhighmargin longlifecycle product offering upgraded improved performance managing product stable earnings platform product invested advanced product brand image technology advanced product feed back platform product cardiac vascular company cardiac vascular company good example business terumo combine two elemental technologiescoating metal alloymetal processing technology example incorporated superelastic metal alloy technology intravascular imaging guide wire laser processing technology ptca percutaneous transluminal coronary angioplasty balloon catheter addition application hydrophilic coating coat product play key role achieving improved accessibility deep blood vessel recent year terumo developed introduced stent combining precision processing microfabrication technology elemental technology stent feature highly flexible design ensure resistance compression bending twisting normal body movement present terumos longterm goal become company global presence realize goal applying technology nurtured cardiac vascular field enhance product pipeline medical imaging peripheral intervention neuroendovascular intervention group elemental technology precision processing miniaturization technology also put good use terumo corporation 65 annual report 2014 employed proprietary zigzag 8 cell2 link structure made nickeltitanium alloy give outstanding flexibility durability misago stent used treating peripheral blood vessel misago stent treating peripheral blood vessel attendant delta occlusion micro balloon catheter used temporarily blocking blood vessel enable access even fine labyrinthine peripheral artery employing design external diameter less 10 mm proven hydrophilic coating attendant delta occlusion micro balloon catheter use hydrophilic coating scepter c cerebrovascular occlusion balloon applying surface balloon portion well better access peripheral artery wind complicated way scepter c cerebrovascular occlusion balloon give hiryu plus ptca dilation catheter durability flexibility conform shape blood vessel employ threelayer structure combining pliable material balloon another highly durable material hiryu plus ptca dilatation catheter terumo corporation 66 annual report 2014 new product ultimaster drugeluting coronary artery stent design goal reduce stress blood vessel improve disease prevention enabled use cobalt chromium alloy unique stent design improve ability navigate convoluted blood vessel facilitate stent placement conformance vessel curvature ultimaster drugeluting coronary artery stent redesigned balloon attendant nexus occlusion micro balloon catheter give capsule shape variable expansion control expanded right amount necessary occlude target vessel placed greater ease attendant nexus occlusion micro balloon catheter general hospital company general hospital company terumo provides medical device system used treatment hospital bedside home terumo adopting technology responsive different way medical device used offer value added medical device leveraging strength pharmaceutical technology medical device designed safety ease use care provider mind medical device specifically home health management preventive medicine surflo v3 iv catheter launched 2012 one example responsive approach technology adoption lower risk hospitalacquired infection surflo v3 employ proprietary design feature aimed reducing risk inadvertent needle stick preventing blood spatter feature improve safety also ease use medical personnel surflo v3 iv catheter terumo corporation 67 annual report 2014 top manufacturer needle wealth technology developed many year apply technology improve patient quality life product meet need uncovered taking user perspective one product nanopass 34 pen needle insulin injection available globally needle thin design unsurpassed world based terumo research nanopass34 insulin injection august 2012 uniquely shaped tip ease pain injecting needle insulin addition combining insulininjection needle technology technology developed many year plastic prefilled syrinx used japan moving forward development highvalueadded prefillable drug agent plastic syrinx overseas pharmaceutical company aiming establish unique business model area plastic prefilled syrinx also working develop highvalue prefillable syringe added product compatible drug considered pharmaceutical company fill difficult offer prefilled syrinx include therapeutic market finished product agent biomedicine drug high demand frontlines medicine another high priority development theme bringing together collection vital data electronic medical recordkeeping range new device aimed reducing administrative burden nursing staff developed thermometer blood pressure blood glucose measurement device use onboard data communication capability automatically enter vital data patient record device free nursing staff turn attention important task negate problem data entry omission mistake delay hr joint series measuring device system communication function terumo corporation 68 annual report 2014 blood management company terumos blood management product centered blood bag used 160 country region around world blood collection method formulation method collected blood sample differ country region terumo teamed optimal partner company region develop supply product ideal local market developed country example blood transfusion therapy recent year come dominated use blood component preparation rather whole blood donor order efficiently separate blood component patient require whole blood terumo andreas hettich gmbh co kg hettich wellestablished german manufacturer centrifuge equipment clinical laboratory usage jointly tacsi automated blood component developed automated blood component processing system processing system tacsi combining terumos proprietary blood bag technology hettichs centrifuge equipment system automates process extracting necessary component blood raw material result system improved precision entire blood component production process dramatically increased work efficiency contributing safety advancement blood transfusion homogenization enhanced quality blood component preparation apheresis therapy blood plasma exchange gathered attention recent year new treatment alternative patient autoimmune inflammatory viral intractable disease cause yet identified terumo develops supply equipment removing patient plasma including pathogenic substance replacing donated plasma used apheresis therapy spectrum optia therapeutic apheresis treating intractable disease system following consolidation terumo group blood management business terumo bct looking ahead spurring advancement plateletpheresis cell therapyrelated technology former caridianbct terumo pursuing rd grow business one deliver greater added value terumo corporation 69 annual report 2014 new field terumo hard work pursing opportunity regenerative medicinea new field promising future growthwhile also striving achieve nextgeneration development build new business traditional field endeavor based corporate mission contribute society healthcare developing new application minimally invasive treatment device new drug delivery device new product focused reducing pain improving postoperative care regenerative medicine terumo embarked research cardiac regenerative medicine 10 year ago technology developed patient cell harvested cultured cell sheet produced applied patient heart present engaged world first therapeutic use cell sheet treatment performed japan view toward commercialization drug delivery device meanwhile area drug delivery device developed device make intradermal injection possible adding traditional intravenous subcutaneous intramuscular pathway drug delivery intradermal delivery known enhance sensitizing potential vaccine therefore expected increase number patient benefit small amount precious vaccine new device brings simplicity reliability intradermal injection hoping lead major innovation daiichi sankyo company limited reached basic agreement april 2012 apply respective expertise field pharmaceutical medical device commercialize new infectious disease vaccine moving ahead clinical development pain management adhesion postoperative qol quality life improvement initiative terumo pursuing development make medical treatment kinder gentler field surgery well acelio intravenous injection 1000mg intravenous injectable acetaminophen antipyretic analgesic aid management cancerrelated postoperative pain went market november 2013 looking expand line pain management product take step add effort help improve patient comfort surgical adhesion another qol issue patient working prevent altogether surgery internal organ become firmly attached surgery site adhesion known occur great frequency regardless type surgery cause complication bowel obstruction chronic pain infertility prevent adhesion developed adhesion barrier form sprayon gel currently undergoing clinical study japan minimally invasive treatment device terumo first time ever taken challenge terumo corporation 70 annual report 2014 developing therapeutic device field urology work performed venture company established silicon valley one world prominent location startup working bring new medical device market another front also developing minimally invasive treatment device help growing number people suffering disease lower extremity fulfill terumos mission contribute society healthcare going beyond traditional area business develop product deliver new value based thorough understanding need medical setting company core intellectual property unique operation freely apply one company endeavor another ongoing effort develop innovative sheet skeletal myoblasts product skill terumo corporation 71 annual report 2014 patent fundamental policy strategic positioning terumo belief management innovative idea patent form intellectual property activity strategically use intellectual property convert profit critical manufacturer terumo group established following two fundamental policy global intellectual property development activity foster culture innovation increase stock intellectual property terumo group formulates promotes global intellectual property strategy closely coordinated rd business strategy ensures innovative idea generated global rd activity including overseas site provide base intellectual property contributes profit terumo group global business operation conducting ip development activity across divisional boundary terumo engineer intellectual property staff work closely together initial stage development invention creation new technology pursued based comparison terumo invention patent product competitor consideration direction taken development activity type intellectual property portfolio built terumo created environment intellectual property staff casually consult engineer promote efficient intellectual property development activity terumos intellectual property department work strengthen patent application activity intellectual property right country region enhanced intellectual property portfolio necessary contributing growth terumo group invention terumo corporation 72 annual report 2014 fostering awareness intellectual property terumo belief raising associate awareness intellectual property stimulating interest topic vital enlarging valuable intellectual property portfolio based belief terumo internally disseminates news intellectual property right various country around world timely manner every year terumo also conduct wide range training program organized intellectual property department program structured systematically according associate level job category ranging basic course specialized practical skill training training program part effort create condition enable endless creation invention technical idea patent portfolio number patent filing recent year terumo selecting number patent filing patent application filing strategychoosing make initial patent application filing japan filing via direct pct application filing u exampledepending specific invention graph show number initial patent application filed terumo past several fiscal year 600 initial filing fiscal year 2012 2013 terumo making initial patent application filing per fiscal year past terumo corporation 73 annual report 2014 number patent filing fiscal year ended march 2014 business segment today terumo file roughly many patent number patent filing fy2013 around new theme unconnected current business segment operation patent direct bearing general hospital cardiac vascular company illustrates terumo committed improvement existing product also investing actively effort drive future business expansion enter new area number patent held region present terumo hold around 3500 patent number patent held region worldwide patent key medical device market japan u europe account 90 figure terumo expecting increase number patent hold china emerging market going forward terumo corporation 74 annual report 2014 measure counterfeit product foregoing activity make clear terumo must constantly safeguard strengthen brand image expands business globally counterfeit product tarnish terumo brand could negatively impact user trust manufacturer terumo obligation take resolute measure clamp counterfeit product includes identifying product early stage global survey one survey terumo determined u company selling radial artery hemostasis device made china called rband terumo belief product infringes patent trademark associated trband product accordingly brought lawsuit u company new jersey federal court february 2013 terumo corporation 75 annual report 2014 global production system recent year terumo pushing ahead globalization production japanese factory serving principal manufacturing facility actively propagating transferring control production technology develop overseas production center mainly asia provide support enable stable production requisite performance quality overseas facility back japan long working create multipolar production configuration established new factory yamaguchi prefecture new construction also planned overseas production new building added existing plant site vietnam increase production interventinal product philippine increase production syrinx needle furthermore second whole new plant built vietnam meet growing demand transfusion product demand also rising coil used treat cerebral aneurysm new factory opened costa rica respond need building global production system key facility japan part asia giving ability meet global demand simultaneously enhancing cost competitiveness strengthening global production system terumo corporation 76 annual report 2014 new japanese facility support global production system terumo yamaguchi corp terumo group new yamaguchi factory terumo yamaguchi corp located within 96000squaremeter yamaguchi techno park began operating april 2014 medical device separation development work production impossible highly advanced highprecision production technology suited transfer overseas terumo positioned production site japan mother factory developing core product technology refining others new yamaguchi factory expected play key role manufacturing catheter dd drug device product requiring use advanced production technology yamaguchi chosen location factory two basic reason one need prepare disaster geographically dispersing production facility concentrated eastern japan reason location yamaguchi city presented attractive benefit term convenient access stable supply electric power outstanding human resource present factory engaged test production catheter guidewires related technology expertise transferred factory japan work proceeding apace transition commercial production coming fiscal year also plan begin production dd product terumo corporation 77 annual report 2014 quality management factory quality assurance system meet international standard since 1995 established quality management system response european medical device directive blended globalstandard system advanced quality assurance system based existing pharmaceutical gmp good manufacturing practice1 standard stepping effort develop quality management system robust enough meet everstricter global requirement strict quality control factory terumo obtained certification iso 134852 international quality standard medical device equipment production site outside japan also keep date development regarding japan pharmaceutical affair act regulatory trend requirement medical device pharmaceutical product outside japan including eu medical device directive u fda regulation strengthened recent year emerging country regulation tightening response accelerating global harmonization strive continually improve quality management system anticipation new trend requirement 1 pharmaceutical gmp pharmaceutical manufacturing guideline issued regulatory authority ensure product safety quality throughout phase receipt material manufacturing shipment product 2 iso 13485 iso standard assure quality medical device equipment terumo quality policy top management set quality policy develop operate quality management system maintain effectiveness division also set quality objective based quality policy way policy devised top management incorporated individual associate objective customer perspective appears top quality policy basis quality assurance terumo corporation 78 annual report 2014 quality policy order deliver safety reliability healthcare field shall pursue product valuable customer understand role quality system practice always review improve way business terumo corporation respect bioethics developing evaluating medical device pharmaceutical terumos first concern dignity life pursue business activity comply relevant law ordinance follow social norm give equal weight science ethic outlined company rule regarding use animal rd product evaluation head animal experimentation group established animal experimentation committee enabling u supplement 3r principle clearly specified 2005 revision japanese law fourth r standing responsibility animal experimentation committee undertakes employee education initiative examines experimentation plan confirms experiment properly carried finished performs inspection determine whether animal properly cared ensure responsibility use animal experimentation assured evaluation performed japan health science foundation organizational approach animal testing compliance basic guideline animal experimentation organization jurisdiction japanese ministry health labour welfare 3r principle first proposed w russel r l burch 1959 three rsreplacement switching research approach use animal reduction use fewer animal refinement reduction pain felt animal principle ethical use animal experimentation japan 3rs codified 2005 revision act welfare management animal terumo corporation 79 annual report 2014 auditing system maintain high quality maintain improve quality implement internal audit objectively evaluate whether quality management system appropriately implemented followed audit conducted associate trained within company perform internal audit result reported top management direct improvement basis continually upgrade quality management system terumo also complies addition undergo several external audit year verify increasingly strict external audit compliance japan pharmaceutical affair act u regulation europe country requirement corporate customer strict quality control facility outside japan role played factory outside japan increase importance provide associate outside japan expertise cultivated japan improving quality turn learn much perspective systematic approach standardization exchange increase factory outside japan also begun introducing shoki ryudo initial quality assessment evaluation method developed japan initial quality assessment system designed reaffirm quality product specification new product customer perspective shifting mass production terumo corporation 80 annual report 2014 stakeholder together customer value communication customer 82 providing information ensure appropriate use 83 listening customer 84 reflecting customer feedback product 85 making relationship corporate activity medical institution transparent 86 together shareholder investor 87 together partner 90 together associate employment motivation 93 providing safe workplace 98 promoting diversity 101 human resource development 106 worklife balance 109 social contribution activity 113 closeup better therapeutic technique healthcare professional throughout world 119 terumo corporation 81 annual report 2014 value communication customer believe terumos role responsibility support healthcare providing safe high quality product service maintaining open honest communication customer part responsibility terumos relationship customer terumos customer include healthcare professional patient general consumer concerned health terumo believe role accurately understand customer need develop product real value place equal importance providing information support ensure customer use product peace mind direct close communication customer carry business activity way contributes healthy living product development service relationship customer chart terumo corporation 82 annual report 2014 providing information ensure appropriate use believe terumos role responsibility support healthcare providing safe high quality product service maintaining open honest communication customer part responsibility ensuring appropriate use medical device pharmaceutical product terumo mr gather swiftly provide accurate information medical institution ensure appropriate effective safe use medical device pharmaceutical product terumo medical pranex comprehensive center technical training medical professional terumo offer range supporting medical training support training area interventional treatment terumo medical pranex injection taking blood sample mr stand medical representative terumo associate provide information medical institution supporting training medical institution help prevent accident usage syrinx transfusion set medical device terumo conduct tpas training medical institution tpas emphasizes key point using individual device enables medical professional learn handson training scenario participant feedback indicates tpas training provides tangible sense situation lead accident demonstrates support training correct understanding use device must based something usage medical device assumption casual advice others showing value program conference quality safety practice medicine benefit tpas training often reported hospital throughout japan terumo corporation 83 annual report 2014 listening customer believe terumos role responsibility support healthcare providing safe high quality product service maintaining open honest communication customer part responsibility terumo call center terumo call center japan receives 300000 call per year general consumer medical institution distributor ensure inquiry related respective class productsfrom designed medical institution home medical careare addressed promptly appropriately call center staff respond expertise field call center staff committed maintaining improving inquiry addressed staff satisfaction caller ensuring urgent inquiry specialized knowledge related patient receiving healthcare home responded hour center also enhancing ability internally reflect customer feedback improvement development product terumo corporation 84 annual report 2014 reflecting customer feedback product believe terumos role responsibility support healthcare providing safe high quality product service maintaining open honest communication customer part responsibility medical safety information management japan accumulate information customer quality safety appropriate use product postmarket surveillance vigilance dept using information promptly develop refine communication delivering various way including attachment important information product web site via industry organization sending mr medical institution facetoface explanation furthermore use accumulated information develop improve product support medical safety training medical institution tpas tpas terumo proactive action safety training program based terumos predictive safety measure providing easytouse product service terumo incorporates ergonomic design many product promote safe simple operation smart infusion system terufusion infusion pump syringe pump apply data communication function greater safety ease use systembased delivery drug onboard drug library function allows setting flow limit specific drug prevent mistake use universal design font make smart infusion system terufusion syringe pump designed facilitate display easy read use medical staff universal design font letter font meticulously designed specifically ease use visibility mind terumo corporation 85 annual report 2014 making relationship corporate activity medical institution transparent communicate terumos contribution life science high ethical standard conduct business activity formulated transparency guideline relationship corporate activity medical institution transparency guideline relationship corporate activity patient organization terumo corporation 86 annual report 2014 together shareholder investor provide stable return shareholder improved corporate value terumo committed open management includes fair timely disclosure communication shareholder investor basic policy regarding shareholder return ensure higher profitability sustainable growth terumo actively promotes appropriate aggressive reinvestment profit work expand corporate value even believe serf interest shareholder lead increased investment value basic policy profit allocation stably increase dividend shareholder commensurate business performance targeting medium longterm dividend payout ratio 30 basic policy regarding ir disclosure aim earn broad social trust terumo discloses information accordance timely disclosure rule set forth financial instrument exchange act tokyo stock exchange based principle transparency fairness continuity addition terumo strives provide timely proactive disclosure information may effective providing better understanding company terumo corporation 87 annual report 2014 communicating shareholder investor general meeting shareholder annual general meeting shareholder present financial result also explain product technology contributing better healthcare video featuring commentary customer associate employee terumos effort realize corporate mission also shown prior meeting meeting venue create display section product shareholder view product exhibition general medical device equipment close way strive meeting shareholder impart deeper understanding terumo facility tour better inform shareholder year invite shareholder visit terumo medical pranex get sense training provide medical professional handle product believe help better understand make also view motivation terumo medical pranex multipurpose training facility medical professional learn use catheter advanced medical technology group physician nurse tour held shareholder strengthen ability work team result briefing result briefing held security analyst institutional investor quarterly teleconference 1st 3rd quarter company representative director key associate attend briefing explaining business result factor behind change management strategy going forward material provided briefing along individual presentation also posted website available result briefing investor terumo corporation 88 annual report 2014 briefing event individual investor provide opportunity direct dialogue individual investor terumo hold company briefing location throughout japan also active exhibiting ir event held tokyo stock exchange others targeting individual investor event individual investor terumo corporation 89 annual report 2014 together partner terumos corporate mission contributing society healthcare reflected procurement activity vital patient healthcare professional able use product safely peace mind therefore exercise great care selecting vetting supplier raw material service raw material procurement policy october 2009 developed human x eco development guideline line commitment people environmentfriendly company guideline making effort reach new level people environmentfriendly procurement particular consideration given following 1 selecting material produce harmful impact next generation reducing environmental impact 2 selecting material used effectively produce waste saving resource based idea maintain fair equitable relationship supplier time continue procure raw material compliance pharmaceutical regulation rule respective country concerned terumo corporation 90 annual report 2014 promoting continuous quality improvement ensure product quality actively seek upgrade quality control raw material also service affect quality management system design production facility mold outsourced production particular stricter fda regulation medical device recent change made important manage quality across global supply chain fully aware quality material service provided supplier impact quality final product supply work supplier make continuous improvement quality conduct regular audit qa system also share qa audit information quality information terumo group production site effort improve quality final product better procurement activity initiative stable procurement terumo manufacture product five factory within 19 factory outside japan distributes 160 country rapid change procurement place top priority ensuring quality stable supply procure material appropriate source deliver high quality product healthcare provider 2011 despite supply interruption caused great east japan earthquake able keep medical supply flowing customer working supplier based shared understanding supply healthcare must come firstthat healthcare must stopped based experience sought cooperation supplier making improvement enhance safety reliability supply chain terumo corporation 91 annual report 2014 supplier survey japan year terumo conduct survey supplier make improvement ensure become trusted purchaser supplier survey includes wide range question involving transaction terumo cover topic including business manner transactional ethic select material ensure stable procurement without interruption healthcare added survey regarding business continuity planning bcp beginning 2011 based response opinion business partner analyze issue facing material division provide feedback factory material division feedback aid resolving issue identified also serf tool verifying direction reflecting customer input procurement activity going forward necessary also meet directly partner provide opinion work improve relationship trust purchasing compliance education measure ensuring good mutual communication supplier terumo brief employee basic rule supplier including supplier selection ordering payment conduct training ensure employee familiar understand act delay payment subcontract proceeds etc subcontractor abbreviated document subcontracting law internal purchasing compliance training addition building awareness internal control also work maintain improve compliance subcontracting law addition terumo promotes encourages understanding subcontracting law actively participating workshop held fair trade commission small medium enterprise agency month government promotes compliance act run series check interview verify compliance status work thoroughly instill reaffirm understanding key point compliance terumo main subcontracting enterprise terumo corporation 92 annual report 2014 employment motivation meaning terumo associate terumo greatly value associate important asset take pain create environment promotes development people place great importance enhancing value individual time expect associate take responsibility enhancing personal value contribute overall development terumo ultimate objective terumo associate work together improve medical care patient around world terumo employee called associate emphasize partnership collaborative working fostering motivating challenging work environment terumo respect individuality associate working foster work climate individual realize maximum potential also provide ample opportunity willingness grow widen field activity goal based initiative enable associate contribute individual strength team enhancing performance creating strong motivating workplace patient day project root motivates associate strong belief work meaningful captured corporate mission remained unchanged since founding 1921 contributing society healthcare y tp day smile pleasure terumo patient day conceived opportunity associate reconnect mission consider mean personally contribute furtherment medical care reflect value provide society y tp day associate listen moving account patient actually struggle overcome illness associate also opportunity visit actual place medicine practiced enables see concrete way connection terumo corporation 93 annual report 2014 every day work frontline patient healthcare y tp day project include collaboration japanese nursing association enhance associate understanding nursing work event conduct give associate chance meet talk medical professional fiscal 2013 y tp day activity held terumo group y tp day location throughout world y tp day abbreviation smile pleasure terumo patient day activity terumo medical product hangzhou co ltd approximately 3300 associate terumo medical product hangzhou co ltd hangzhou plant largest overseas business location function critical production facility distribution center fall athletic meet carnival terumo group product enable supply family day increasingly highquality product develop people even higher skill ability undertaken various initiative aimed creating condition allow associate work vitality pride hangzhou plant spring example offsite event held associate refresh mentally physically fall organize athletic meet attended entire workforce family large stadium provides thrilling venue heated though friendly competition provides powerful way foster unity addition plant worker union frequently arranges trip organizes activity various union member club including flower arranging cooking popular among female associate plant dormitory single employee governing committee also actively terumo corporation 94 annual report 2014 organize event 5 activity seiri streamline seiton organize seiso clean seiketsu hygiene shitsuke selfdiscipline study group birthday party contribute making life dorm enjoyable familylike believe continually holding activity deepens relationship among associate contributes unity hangzhou plant ultimately form strong foundation terumos production sale endeavor aim deliver product safely peace mind 360 feedback motivation survey japan help create highly motivating challenging workplace open candid communication forward looking spirit regularly conduct 360 feedback survey executive general manager associate engagement survey also carried japan based associate result survey provides valuable insight management leadership team enabling u continually strive make terumo even better place work ace inhouse job posting system japan terumo operates inhouse job posting system called ace set 1997 system enables associate range department job type enhance career taking new challenge opportunity example management position medical device venture company terumo established u recently posted japan based associate unrelated division applied successful ace applicant selected happily working new job u introducing product trade show africa system open associate regardless age gender present opportunity gain experience develop business professional strong desire move career next level terumo corporation 95 annual report 2014 far 100 associate taken advantage ace system talent pool 33 global candidate also set half already global assignment outside japan others accelerated development position within japan preparing transfer abroad fiscal 2013 total 55 application 11 individual passing screening process winning chance pursue new area opportunity genbano hokori award honor frontline award terumos growth supported highly visible associate achieve outstanding result also many associate consistently produce solid result work diligently behind scene every day reward recognize associate genbano hokori award literally honor frontline award presented year winner genbano hokori award fiscal 2013 fiscal 2013 award presented five associate chosen around 100 nominated fellow associate among recipient veteran associate working distribution overseas plant since first opened associate charge transferring production knowledge expertise younger generation associate managementworker dialogue terumo recognizes healthy managementworker relationship based trust mutual understanding extremely important u grow develop together associate input worker union treated valuable feedback take action resolve issue way acceptable management associate dialogue top management take place meeting uc union company discussion side opportunity fully state view relationship terumo corporation 96 annual report 2014 management worker union one work partner bring growth development company union member outside managementworker dialogue view freely exchanged throughout company survey conducted worker union feedback received using different channel data associate consolidated staffing data geographic area individual fy2011 fy2012 fy2013 japan 5048 5011 5070 europe 1837 1892 1814 america 5177 5656 5936 asia others 6050 6334 6443 total 18112 18893 19263 associate gender location standalone data terumo corporation individual fy2011 fy2012 fy2013 male japan 4123 4065 4072 female japan 664 656 639 terumo corporation 97 annual report 2014 providing safe workplace basic policy terumo group strive create safe workplace associatesvalued asset companycan realize full potential terumo employee called associate emphasize partnership collaborative working occupational health safety management structure protect safety associate japan occupational health safety management committee hold regular meeting factory rd headquarters sale office head office prevent industrial accident minimize impact occur continually undertake initiative aimed ensuring health safety workplace goal zero industrial accident initiative include 5 program review danger zone risk mitigation measure information shared report committee others fiscal 2013 experienced industrial accident required associate take three day work three accident fiscal 2012 continue effort avoid industrial accident goal zero serious accident death industrial accident resulting lost working day frequency1 seriousness2 fy2010 fy2011 fy2012 fy2013 accident resulting lost working day 2 2 3 0 frequency 066 097 168 000 seriousness 0 0 001 0 1 rate occurrence number accident resulting injury death per million working hour 2 seriousness lost working day per 1000 working hour terumo corporation 98 annual report 2014 employee health management terumos mission improve medical care society take various step protect health associate encourage aware health physical condition addition regular health checkup sponsor screening lifestylerelated disease mainly cancer cooperation health insurance union industrial health staff offer individualized health related guidance advice furthermore fiscal 2014 undertaken new initiative call terumo health action stimulate awareness dental health help associate avoid lifestylerelated oral health disease mouth well sponsoring dental health checkup provide subsidy care support towards treatment associate would like stop smoking unsuccessful receive stop smoking subsidy treatment smoking cessation clinic encourage associate try support succeed first time provide subsidy repeated attempt following year beyond support better mental health well physical wellbeing also offer variety lecture including stress management training new hire general employee team member mental health care management method leadership staff terumo corporation 99 annual report 2014 compliance prevention harassment terumo group formulated terumo group code conduct sakura rule provides guidance aspect behavior conduct associate expected adhere daily business activity fulfilling role outstanding corporate citizen associate bear heavy social responsibility obeying law also demonstrating ethical behavior aspect work toward end terumo workplace hold annual event aimed promoting deeper understanding code conduct emphasizing compliance preventing harassment addition training incorporating example reflect familiar situation applied daily work regularly held management position understanding expected regarding harassment particular established system harassment victim receiving ethically questionable treatment immediately seek help male female responder provide advice internally protecting privacy seeking assistance system also make possible consult external attorney needed terumo corporation 100 annual report 2014 promoting diversity basic policy respect human right stimulate diversity terumo group work hard promote respect individual culture discriminate whether race nationality gender religion disability basis would violate human right believe diversity associate powerful engine drive current future growth striving accept wide range differing value promoting mutual recognition diversity aim company differing idea knowledge intermingle creating new value established diversity promotion department work raise awareness diversity issue among associate continually promote diversity company variety perspective terumo employee called associate emphasize partnership collaborative working promoting active participation female associate first step channeling mutual recognition diversity corporate growth terumos top management made commitment promoting active participation female employee forged ahead various initiative aimed creating suitable environment climate awareness enable woman thrive workplace example include mentoring system woman seminar woman wanting resume career terumo mentoring system system pair female associate leadership position working different part company different age share experience idea broaden perspective support one another career growth raising awareness skill female associate woman assume leadership role within terumo contribute fresh perspective value fiscal 2013 group training womens creation mentoring system terumo corporation 101 annual report 2014 career resumption seminar terumo seeing rising number men woman want continue career caring child providing nursing care fiscal 2013 began holding career resumption seminar female associate currently child nursingcare leave supervisor purpose seminar discus associate continue meet care responsibility returning work fiscal 2013 careerresumption seminar also career continue provide opportunity associate supervisor discus new way working furthering career fiscal 2013 conducted program aimed helping female manager improve mentoring skill bringing together female associate leadership position throughout japan group training also provided participant opportunity meet positive role model build support network fiscal 2013 conducted program aimed helping female manager improve mentoring skill bringing together female associate leadership position throughout japan group training also provided participant opportunity meet positive role model build support network number female manager terumo gradually rising march 31 2014 40 woman management position 42 entire management staff continue advance initiative enable ambitious female associate play greater role terumo fiscal 2013 female manager seminar terumo corporation 102 annual report 2014 number female manager figure terumo corporation japan operation japanese staff fulltime temporary assignment group company engagement people organization country promote better understanding japanese associate counterpart country hold waigaya event participant share information market work also different management practice also engage open wideranging discussion topic career path waigaya discussion associate australia japan terumo corporation 103 annual report 2014 female associate working overseas career began 1984 terumo sale agent worked specialist dialysis product time rare healthcare professional take position within commercial business enormous challenge involved nearly entire range terumos offering course included hospital blood management product also charge radifocus guide wire product foundation portion cardiovascular business always confident ability build career 2001 example entered college program obtain degree marketing year completed degree gained opportunity work marketing manager since 2007 marketing manager terumo chile devising strategy seizing market opportunity driving home business plan analyzing result building relationship customer developing investment plansmy job many differing aspect love recently primary challenge increase sale argentina part call south cone southernmost part south america includes chile argentina uruguay paraguay also continue study take career next level marketing manager terumo chile ltda terumo corporation 104 annual report 2014 rehiring system terumo expert system terumo introduced te terumo expert system fiscal 1998 way rehire retiree outstanding skill expertise many associate brought back te continue make expertise developed many year terumo expert work highly specialized area also wide range place contributing company drawing wealth experience provide guidance advice younger associate number percent associate rehired te employment people disability providing job opportunity fit capability aptitude individual terumo advancing employment people disability pursue rewarding life independent member society march 31 2014 people disability made 203 workforce japan legally mandated rate 200 looking future continue expand opportunity individual fully exercise capability terumo corporation 105 annual report 2014 human resource development basic policy terumo belief true corporate value lie collective worth associate work company human resource development based practical skill acquired onthejob training ojt variety training program designed supplement ojt believe effective learning come interest associate heart therefore associate understand value necessity training self nominate various program terumo employee called associate emphasize partnership collaborative working terumo training scheme 1 terumo global leadership meeting 2 terumo global leadership program terumo corporation 106 annual report 2014 promoting spirit monozukuri terumo promoting transfer skill experience monozukuri spirit veteran associate younger colleague devoted significant effort developing curriculum training environment instructor fiscal 2013 conducted training 220 associate including participant overseas another step pursuit effort established production human resource development center april training vietnamese technician 2014 te associatesveteran employee rehired mandatory retirementlead nurturing younger generation moving forward aim globally accelerate development human resource taking key role production technology quality assurance management ensure monozukuri spirit keep thriving terumo global human resource development increasing globalization make essential terumo group develop highly motivated human resource equipped diverse communication skill needed work effectively people culture also necessary leadership capability japan terumo global leadership program tglp develops leader practical capability lead global business program involves 24 participant aged 20 40 selected around 100 applicant series seminar held five month participant learn capture true nature management issue leadership challenge group discussion dialogue fiscal 2013 tglp closing ceremony associate relevant department participant develop proposal innovation way enhance current business presented terumos leadership successful proposal become actual high profile project terumo corporation 107 annual report 2014 training international business skill japan terumo offer global challenge program international corporate program way associate gain international business skill relevant work experience program target young associate desire intent work abroad future international corporate program terumo sends associate emerging market country participant fiscal 2013 apply experience skill local organization set overseas work experience address social issue fiscal 2013 program participant spent program two month indonesia working ngo arranges medical clinic low income people addressing need hand participant also enlisted cooperation associate back japan support obtaining mba qualification terumo established system developing human resource suited global management support associate around world actively striving improve earning mba qualification system allows associate take leave long needed complete study allows take additional 100 day unused paid leave prior start period leave study addition company may approve interestfree loan tuition living expense certain condition contribute towards entrance fee tuition also appreciate great benefit type opportunity provide mix people different company culture terumo corporation 108 annual report 2014 worklife balance basic policy terumo aim increase work style flexibility hour location etc better enable associate work enthusiasm exercise capability fullest see employment system give rise flexible work approach system allow adjustment child care nursing care life event measure help associate meet home workplace responsibility step called act advancement measure support raising nextgeneration child continue take action need arise terumo employee called associate emphasize partnership collaborative working terumo corporation 109 annual report 2014 child nursingcare support system following primary system place march 31 2014 help employee meet child nursingcare workplace responsibility child nursingcare support system system description1 child long term leave taken child reach age 3 30 day care maternitypaternity unused paid holiday taken leave shortened working hour shortened 2 hour per day child working hour finish elementary school approximately age 6 adjusted working start end time regular working day moved forward hour backward 1 hour child finish elementary school approximately age 6 nursing special leave leave taken cumulative total 3 year family care2 member requiring nursing care 30 day unused paid holiday taken shortened working hour shortened 2 hour per day cumulative working hour total 3 year adjusted working start end time daily working hour moved forward backward hour 1 hour cumulative total 3 year hourbased paid paid leave may taken unit 1 hour reason leave 1 content excerpted child nursingcare support system 2 nursingcare leave leave shortened working hour adjusted working hour used cumulative total 3 year terumo corporation 110 annual report 2014 approved display kurumin mark fiscal 2014 nextgeneration certification mark kurumin mark indicates company proactively pursues diversity terumo right display right display kurumin mark awarded japan ministry health labour welfare company recognizes formulated action plan helping employee meet child care need fulfill work family responsibility company approved use kurumin mark display product business card advertising swaddled infant mark design express willingness displaying company take step help employee raise child terumo committed fostering working environment associate approach work vigor free fully exercise capability encouraging men take childcare leave number male associate take childcare leave recently begun increase birth child prime opportunity rethink one approach work posting account associate taken childcare leave company intranet promote wider understanding system help create atmosphere make easier men choose participate child rearing terumo corporation 111 annual report 2014 number associate taking maternity childcare leave standalone figure terumo corporation japan operation individual fy2009 fy2010 fy2011 fy2012 fy2013 associate taking maternity leave 21 22 19 22 24 associate taking childcare leave woman 20 22 28 27 26 men 1 8 7 9 14 workathome system terumo adopted workathome system give associate choice working home day childcare nursingcare responsibility make difficult come office committed expanding choice enable associate make skill knowhow demand associated child care nursing care example make working usual manner difficult careerreturn system terumo opened pathway rehiring associate left marriage child nursingcare responsibility relocation spouse careerreturn system expands range employment choice associate want resume career terumo supporting associate interrupt career return work making possible make good use broad experience skill contribute terumos growth noovertime day encouraging use paid leave terumo promotes work efficiency strict management time beginning workday establishment noovertime day part policy maintaining workplace environment work time work offtime rest set company holiday encourage associate take paid day terumo corporation 112 annual report 2014 social contribution activity providing information manage health enlightening website preventing subarachnoid hemorrhage march 2014 terumo established enlightening website preventing subarachnoid hemorrhage japanese provide patient family accurate objective information cerebral aneurysm key cause subarachnoid hemorrhage content site assembled oversight dr nobuyuki sakai director neurosurgery stroke center kobe city medical center general hospital medical institution renowned treatment cerebral aneurysm purpose website promote correct understanding subarachnoid hemorrhage provide user useful prevention information diagnosed brain disease site provides latest medical information easy understand term help allay fear answer question terumo created numerous website providing information society large improve daily health management also created targeted website including devoted health topic body temperature another focused preventing fall among elderly enlightening website japanese explanation cerebral aneurysm key cause subarachnoid hemorrhage terumo corporation 113 annual report 2014 contribution development healthcare terumo life science foundation first established 1987 terumo life science foundation relaunched registration public interest incorporated foundation april 1 2012 purpose foundation contribute medicine better health promoting advance life science technology subsidy form assistance three part foundation mission presentation ceremony first support life science research holding academic conference fiscal 2013 subsidy granted three special research project addressing topic regeneration approach using neovascularization inducing biomaterials treat brain injury 25 general research project 31 international exchange academic conference ceremony award subsidy recipient held march 2014 date foundation disbursed total practical lesson generating around 133 billion subsidy 901 recipient cellular sheet science café part second aspect missionawards related operationsthe foundation selected recipient second annual terumo global science prize commemorating 25th anniversary founding prize awarded outstanding researcher making unique contribution regenerative medicine biomaterials research winner second annual prize professor sung wan kim university utah professor kim formally presented prize presentation ceremony held july 2014 promoting education third aspect foundation mission 2009 japanese website called life science dokidoki research class created provide life science related information junior senior high school student today site provides young user easytounderstand information cuttingedge research researcher life science second book summarizing site content published terumo corporation 114 annual report 2014 august 2013 foundation invited 31 high school student seven prefecture kanto region attend event joint institution advanced biomedical science operated tokyo womens medical university waseda university participant science café able experience simulator example latest technology regenerative medicine greatly impressed fiscal 2014 activity similar conducted fiscal 2012 work contributing wider community presenting annual christmas gift hospice japan year around christmas time team terumo associate decorates outside wall terumo shonan center building christmas light christmas day team put firework display local community hospice terumo male choir sings christmas carol hospice patient program started 1997 bring christmas cheer hospice patient family local resident terumo male choir singing continued every year since 2013 christmas holiday season hospice able enjoy variety illumination display including one depicting reindeer illumination display firework terumo corporation 115 annual report 2014 local activity terumo conduct many social contribution activity local community business site japan example terumo associate social contribution local activity weekly cleanup public road park near head office clean activity chuo ward tokyo held may cleaning tama river bank tokyo every spring fall cleaning surroundings shonan center cleaning surroundings fujinomiya factory cleaning surroundings ashitaka factory center cleaning surroundings sale branch note activity held fiscal 2013 offcampus learning assistance various terumo facility welcomed junior high school student taking part environmental study field trip student learned environmental initiative taken site environmental consideration incorporated product environmental activity undertake close home junior high school student afterward received many message student hosted offcampus happy learned terumos product learning experience importance protecting environment japanchina friendship initiative terumo cooperating project set give chinese university student chance visit japanese company understanding japan sponsored japanese chamber commerce industry china beijing japanchina friendship association project brought chinese student japan spring fall student tour terumo annually since 2005 occasion host 40 student terumo corporation 116 annual report 2014 one rotation six beijingarea university student visit medical pranex company headquarters plant research facility etc related member japanese chamber commerce industry china observe society industry including agricultural community culture aspect japan also meet japanese university student spend night japanese family farewell party terumo host visiting student tour terumo medical pranex experience medical training program aimed helping see medical device medicine different perspective terumo employee homestay host provide outstanding student guest first direct exposure daily custom culture japan giving future leader china chance experience delight warmth japanese culture believe chinese student interact people company japan deepen relationship two country lead greater friendship mutual understanding future terumo continue participation going forward donation aid typhoon victim philippine terumo donated syrinx medical device worth approximately 19 million yen together financial contribution 3 million yen aid victim typhoon struck philippine november 2013 addition subsidiary u europe southeast asia made donation money medical device total value around 50 thousand dollar making donation embassy philippine terumo corporation 117 annual report 2014 blood donation terumo carry annual blood drive factory branch japan fiscal 2013 total 1173 associate 23 location across japan donated blood terumo contribution society include manufacture blood bag also blood donation activity inhouse blood donation terumo corporation 118 annual report 2014 key characteristic medical device unlike pharmaceuticalsin effectiveness product determines therapeutic efficacyit optimal medical device used medical professional practice appropriate therapeutic technique high degree therapeutic efficacy obtained globalization taking hold activity medical professional numerous medical specialist nurse emerging region world study therapeutic technique u europe japan return home country share learned result product medical device coming demand new market globe efficacy device used field intervention intravenous therapy depends greatly manual dexterity medical professional using therefore improving product usability critical monozukurior art manufacturingperspective importance medical professional simply growing accustomed using cannot underestimated terumo belief disseminating advanced medical technology academic information product also training duty medical device manufacturer whose product choice medical professional across globe supporting development healthcare professional throughout world mock hospital equipped latest device 2002 terumo opened terumo medical pranex comprehensive medical training facility within rd center assist healthcare professional throughout world improve skill replete various type simulator operating room realworld facility catheterization laboratory terumo medical pranex essentially mock hospital faithful recreation medical environment improvement coronary neurovascular intervention therapy skill safety improvement emergency response hospital home even basic skill new nurse facility one meticulous training undergone realistic medical environment used around 10000 healthcare professional around world every year terumo corporation 119 annual report 2014 working jica promote tri central south america 2014 interventional system division terumos cardiac vascular company submitted proposal japan international cooperation agency jica initiation project promotion private sector technology toward social economic development developing country publicprivate partnership project proposal selected among many competitor terumo japanese medical institution commissioned jica conduct training use transradial coronary intervention tri interventional treatment us blood vessel wrist entry point approaching coronary artery training provided period two year medical professional mexico colombia argentina brazil four country technique used relatively infrequently purpose project 1 promote adoption tria treatment technique mean less physical stress patient lower medical expensesin country heart disease become serious problem 2 contribute better health country increasing treatment rate people heart disease also thought initiative project could contribute friendly relationship japan participant country first phase project physician mexico colombia came japan may 2014 participate training terumo corporation 120 annual report 2014 disseminating information efficacy safety new technology product terumo gather widely disseminates academic information broad variety medical field every year actively participate academic conference held medical professional across globe use opportunity disseminate information latest therapeutic technique product physician specialist live demonstration specialist conference interventional therapy conference presentation clinical trial widely distribute information utility new product efficacy therapy furthermore field general hospital business academic conference provide information new therapy technique safety operational efficiency improvement initiative topic effort also extend patient family reach channel like health information website site began march 2014 example posted information subarachnoid hemorrhage topic well understood general public site offer easily understood explanation characteristic treatment prevention cerebral aneurysm cause subarachnoid hemorrhage disseminating objective accurate information contributing proper treatment health problem terumo corporation 121 annual report 2014 environment ehs management 123 goal achievement 128 material flow 133 developing environmentallyfriendly safety product 134 initiative deal climate change 140 effective use resource 145 proper control chemical substance 150 initiative biodiversity conservation 157 environmental data fiscal 2013 160 history environmental initiative 162 terumo corporation 122 annual report 2014 ehs management formulation terumo global ehs policy october 2012 revised basic environmental policy instituted terumo global ehs environment health safety policy outline stance reducing impact business activity environment conserving biodiversity health safety associate work policy applies entire terumo group form basis corporate activity information occupational safety health initiative please refer following page terumo global ehs policy terumo group aim good corporate citizen striving reduce environmental impact associated business activity ensure safety health employee based corporate mission contributing society healthcare 1 take action based environmental health safety ehs management system establish following voluntary goal strive continuous improvement 1 reduce environmental impact ehs risk business activity 2 develop environmentally friendly safe product 3 effectively use appropriately manage energy resource 2 comply law ordinance agreement rule relating ehs country 3 carry environmental conservation activity strive conserve biodiversity member society community 4 work ensure safety health employee business activity strive create safe comfortable work environment 5 strive prevent ehs accident environmental pollution occupational injury emergency strive prevent damage spreading responding swiftly appropriately 6 systematically continuously provide education training strive increase ehs awareness 7 actively disclose information pertaining ehs activity strive communicate society community established october 2012 ehsenvironment health safety terumo corporation 123 annual report 2014 ehs management system established line terumo global ehs environment health safety policy ehs policy developing ehs management system integrate approach issue ehs policy related target plan deliberated decided ehs committee key part terumos focus sustainability business reflected ehs activity terumo group site worldwide ehs expert subcommittee formed provide advice ehs committee key area addition ehs audit committee oversees conduct ehs related internal audit site confirm effectiveness operational status system well compliance relevant law regulation going forward focus continuous system improvement gradually acquire iso 14001 certification environmental management system ohsas 18001 standard occupational health safety management system terumo group production site fujinomiya factory fujinomiya city shizuoka prefecture terumo penpol ltd kerala india obtained certification fiscal 2013 companywide organization promoting ehs management system terumo corporation 124 annual report 2014 iso 14001 ohsas 18001 certification gained fujinomiya factory fujinomiya factory created ehs management system manage environmental health safety matter integrated fashion based terumo global ehs policy obtained iso 14001 environmental management ohsas 18001 occupational health safety management certification october 2013 fujinomiya factory committed maintaining continuously improving management system lower environmental impact manufacturing activity secure health safety everyone working premise ehs audit prevent legal violation environmental problem reduce present future environment safety health risk conduct internal ehs audit based terumo ehs committee standard audit cover factory rd center head office sale office japan well terumo group company including overseas site audit task 1 check operational status ehs management system 2 check compliance ehsrelated law ordinance 3 check ehsrelated performance audit identifies instance noncompliance request corrective preventive actionsresponse form issued followup check performed ensure corrective preventive action implemented functioning matter constitute noncompliance thought warrant ongoing observation written followup check performed matter question reviewed following year audit terumo corporation 125 annual report 2014 fiscal 2013 ehs internal audit result regarding compliance ehsrelated law ordinance serious violation four minor violation identified corrective preventive action implemented regarding management environmental risk item individual business site determined efficient management system place serious effort made achieve voluntary goal internal audit terumo china regarding occupational health safety holding co ltds hangzhou plant matter currently addressed determined action taken result improvement result external environmental audit fiscal 2013 auditing wastetreatment contractor confirm sludge waste plastic generated terumo appropriately processed throughout stage treatment prepared checklist use regular audit waste collection disposal contractor fiscal 2013 conducted audit 32 contractor audit wastetreatment contractor result external onsite inspection fiscal 2013 prefectural municipal authority conducted environmental onsite inspection tested water sample factory rd center based water pollution control act air pollution control act waste disposal public cleansing law act confirmation etc release amount specific chemical substance environment promotion improvement management inspection government thereof inspection test resulted issuance authority remedial instruction inspection authority terumo corporation 126 annual report 2014 ehs education environmental safety training associate ensure solid understanding terumo global ehs policy ehs activity everyone terumo expected engage conduct training tailored sale production type business site associate including new hire required participate promote greater environmental health safety awareness also distribute information via terumo intranet hold ecocampaigns associate associate ehs training family ehs award systemterumo humanecoaward created terumo humaneco award system fiscal 2012 recognize environmental safety health contribution element terumo group worldwide award encourage associate become involved environmental safety health activity share related information initiative selected award ceremony recognition fiscal 2013 listed example shared throughout terumo group project award recipient resource saving filter used remove white blood cell fujinomiya factoryrd headquarters energy saving change air conditioning control ashitaka factory approach building 1 4 terumo corporation 127 annual report 2014 goal achievement environment safety performance fiscal 2016 voluntary fiscal 2013 fiscal 2014 initiative fiscal 2013 target targetsmediumterm assessment target begin application management system integrating introduce group environmentalsafety environmental health health coverage expand application safety management view toward group system ehsms gaining 3rdparty ehsms kofu domestic production site certificationfujinomiya factory obtain 3rdparty ehs factory certification management system continue internal construction terumo group ehs audit conduct environmental expand application move forward health safety group ehsms creation compliance training principal overseas global ehsms production site manual assemble information legal revision terumo corporation 128 annual report 2014 fiscal 2016 voluntary fiscal 2013 initiative fiscal 2013 target fiscal 2014 target targetsmediumterm assessment continue operating workrelated workrelated death workrelated death serious death serious serious accident accident accident cut workrelated fewer accident cut workrelated accident half requiring time accident compared compared fy2013 previous previous fiscal reduction fiscal year year accident risk continue environmental develop procedure continue operating impact assessment responding serious environmental environmental accident continue risk accident assessment emergency continue develop achieve concrete product comply result rohs development bring 3 directive build planning least humaneco product assurance one humaneco development market system productproduction process terumo environmentally advance corporation japan conscious development development site safe product product reflect production consideration advance cooperation process humaneco among business site develop technology development production use cfc directive technology environmental use cfc hcfc safety concern 225 terumo corporation 129 annual report 2014 fiscal 2016 voluntary fiscal 2013 fiscal 2013 fiscal 2014 initiative targetsmediumterm target assessment target improve co2 advance effort emission per unit save energy consolidated net reduce electricity sale 4 usage reduce co2 compared emission per unit previous fiscal year participate consolidated net sale challenge 25 30 relative reduce energy campaign fy2005 business cost 1 implement internal location japan compared bau eco campaign overseas terumo manufacturing site corporation promote eco effective use manufacturing driving energy longterm target research site resourcesreduction reduce 50 japan reduce final co2 emission fy2025 disposal waste bau business less 05 usual period total waste action business location taken excluding sale office japan reduce final increase waste disposal waste recycling 85 advance use less 05 higher group electronic total waste terumo company japan manifest corporation overseas throughout business location manufacturing site group japan terumo corporation 130 annual report 2014 fiscal 2016 voluntary fiscal 2013 initiative fiscal 2013 target fiscal 2014 target targetsmediumterm assessment determine status chemical substance establishment management chemical substance prepare guideline maintain management system terumo dichloromethane compliance guideline corporation release 99 less business location proper japan continue voluntarily control measure property line chemical keep move forward effort concentration substance dichloromethane control release ethylene oxide emission less property line reduction 100 per year concentration continue comply emission eog dichloromethane reach concentration chemical substance overseas property line chemical substance adjacent improve work regulation residential area environment 43 organic solvent μgm3 business handled location japan terumo corporation 131 annual report 2014 fiscal 2016 voluntary fiscal 2013 fiscal 2014 initiative fiscal 2013 target targetsmediumterm assessment target conduct internal work ngo eco campaign advance expand continue mt fuji expand participation biodiversity preservation reforestation project business location activity preservation japan biodiversity continue employee expand mt fuji participation eco expand mt fuji reforestation project activity reforestation include ongoing care project planted tree include social environmental reporting issue social annual report environmental improve quality enhancing content report 2013 annual report information process disclosure conduct advancement integrate economic environmental ehs social month initiative communication environmental information continue environmental implement ehs construct ehs e safety education education applying learning system associate elearning business location business location japan japan terumo corporation 132 annual report 2014 material flow energy raw material input use identify environmental impact term co2 wastewater waste output business activity use data indicator activity aimed reducing environmental impact going forward material flow related terumos business activity business activity material flow data terumo corporation operation japan coefficient used calculating co2 emission related electricity use provided electric power provider prtr pollutant release transfer register distributionrelated nox emission calculated using coefficient japanese environment ministry environmental activity evaluation program april 2002 terumo corporation 133 annual report 2014 developing environmentallyfriendly safe product goal healthcare friendly people environment terumo develops product friendly healthcare professional patient global environment humaneco development guideline terumo aim make medical treatment kinder gentler mean making medical procedure safer efficient creating technology place less physical stress patient prevent infection facilitate work medical professional lead medicine friendly environment infection medical accident occurs becomes necessary use medical resource would needed otherwise believe therefore developing product emphasize safety efficiency usage well effectiveness good environment terumo established humaneco guideline set four principle 24 directive developing product friendly people environment promote effort display humaneco logo best example design philosophy humaneco development guideline terumo corporation 134 annual report 2014 measure hazardous substance pioneer removal mercury healthcare practice conference plenipotentiary minamata convention mercury held october 2012 convention adopted signed convention take effect essentially prohibit manufacture import export product containing mercury 2020 terumo ceased production mercury thermometer 1984 30 year since developed digital thermometer digital blood pressure monitor device mercuryfree safer people friendlier environment digital thermometer digital blood pressure monitor promoting pvcfree dehpfree product terumo help reduce release toxic gas incineration polyvinyl chloride pvc promoting use pvcfree packaging also use alternative di2 ethylhexyl phthalate dehp whenever possible since concern may biologically harmful iv solution set iv solution bag cardiovascular circuit terumo corporation 135 annual report 2014 saving resource cost minimally invasive economical cardiac catheter introducer kit cardiac catheterization performed inserting catheter either wrist groin inserting wrist entail fewer complication postprocedure bleeding less invasive terumo developed innovative introducer kit feature sheath thinner finely formed wall smaller outside diameter narrower sheath make treatment option available patient small artery cardiac catheter introducer kit also reducing cost resource usage associated post procedure complication ptca balloon catheter various type therapy developed ptca balloon catheter used various type therapy using advanced material improving way balloon folded product made possible reduce number catheter used provide treatment patient mean comfortable patient help save resource reduces treatment expense ptca balloon catheter ptca balloon catheter medical device used widen clogged blood vessel inflating balloon tip terumo corporation 136 annual report 2014 integrationthick liquid meal need water adjustment unlike conventional product fluidity thickness must adjusted creating need bottle readytouse product produce less waste eliminates labor associated washing bottle moreover mixture water thick liquid nutrition reduces burden healthcare professional caregiver humaneco certified thick liquid meal integrationcombining several drug one bag product put infusion liquid required single bag simplifies mixing process help prevent microbial external contamination coinjection also eliminating potential accident involving needle product also help save resource reduce medical waste eliminating need medical equipment used preparing infusion bag fiscal 2012 introduced version infusion solution product mechanism prevent administration liquid separate compartment bag mixed safely infusion fulcaliq registered trademark mitsubishi tanabe pharma corporation integrationprefilled syrinx prefilled syrinx eliminate need suction dissolution also replace ampoule vial besides boosting productivity also help prevent microbial contamination problem due syringe misidentification accident involving needle made plastic prefilled syrinx less fragile easier dispose term waste separation weight compared glass syrinx injection solution prefilled syrinx terumo corporation 137 annual report 2014 integrationoxygenator integrated arterial filter integrating oxygenator arterial filter one device reduced number part used blood circuit well material used oxygenator integrated arterial filter lighter smaller product reduced size weight syrinx maintaining volume functionality improvement enabled 25 reduction waste term weight reduction size also reduced cost packaging transportation also achieved 40 reduction weight continuous syringe capd bag ambulatory peritoneal dialysis capd bag used home healthcare effort reduce household waste flexible portable blood bag used 100 country aiming improve safety transfusion terumo marketed first blood bag produced japan 1969 compared product made glass terumos plastic bag incorporating blood collection tube container offer outstanding flexibility portability reducing transportation cost well waste volume blood bag terumo corporation 138 annual report 2014 packaging waste volumeweight reduction developed certified angiographic kit eliminated excess packaging procedure providing product needed surgery together single set reduced weight waste developing better method form product packaging redesigning shape tray allowed 53 reduction material compared terumos conventional solution pack humaneco certified angiographic kit easier use safer improving usability patientsblood glucose monitor voice guidance device large easily readable lcd screen voice guidance feature enable user hear reading error message raised button separated easy distinguish touch ensure diabetic patient impaired sense vision touch use device easily product gained good design award fiscal 2012 blood glucose monitor closed infusion system chemotherapy drug reduces exposure risk chemotherapy drug help control cancer many reported pose potential risk health handling due carcinogenicity terumo chemoshield system infusion chemotherapy drug eliminates risk closed system prevent exposure drug process administration disposal since need use needle prepare infusion system enhances closed infusion system safety medical personnel preventing risk needle chemotherapy drug accident terumo corporation 139 annual report 2014 initiative deal climate change climate change due global warming among critical environmental problem threatening humanity unusual weather event expected cause increase natural disaster impact ecosystem way serious health impact terumos business activity also subject greater risk working prevent global warming using energy effectively applying renewable energy taking step help prevent climate change target reduction co2 emission scope12 1 global2 co2 emission fiscal 2013 equivalent 70 emission per unit net sale fiscal 2005 significantly better comparable figure fiscal 2012 nearly 99 co2 emission accounted production plant rd center ehs expert subcommittee energy take lead planning advancing energy efficiency global warming measure later implemented individual business site fiscal 2013 invested mainly fuel conversion turbo chiller highefficiency oncethrough boiler led lighting efficiencyboosting device also repaired steam leak took energysaving measure based regimen regular inspection implemented simple yet effective energysaving measure office including setting thermostat appropriately turning unneeded lighting holding ecocampaigns involve entire terumo group energysaving 1 scope terumo us ghg protocol scope 1 2 standard calculate greenhouse gas emission scope 1 standard direct emission greenhouse gas corporate facility plant scope 2 standard indirect greenhouse gas emission associated consumption purchased electricity scope 3 standard terumo employ greenhouse gas emission business activity 2 global business site japan overseas production site mid longterm goal global reduce co2 emission per unit consolidated net sale 50 relative fiscal 2005 level fiscal 2025 terumo corporation 140 annual report 2014 trend co2 emission per unit consolidated net sale co2 emission breakdown scope 1 scope 2 emission fy2013 1 business site japan 2 overseas production site 3 electricityrelated co2 conversion coefficient japan set based actual result obtained individual customer fy2005 overseas electricityrelated co2 conversion coefficient regional coefficient 2005 published iea co2 emission fuel combustion 2012 co2 emission breakdown scope 1 scope 2 emission fy2013 scope 1 scope 2 total japan 49200 72500 121700 overseas 31700 99000 130700 global 80900 171500 252400 renewable energy usage photovoltaic power mwh 258 biomass gaskg 975 terumo corporation 141 annual report 2014 initiative fujinomiya factory fujinomiya factory fujinomiya city shizuoka prefecture us large amount steam sterilize product considering way increase steam supply efficiency replaced flueandsmoketube boiler high efficiency highpressure oncethrough boiler combined highefficiency high deactivators new approach supplying steam pressure oncethrough boiler much responsive load change helped u increase steam supply efficiency around 13 also produced fuel saving 550 kl reduced co2 emission roughly 1000 ton effort terumo penpol limited terumo penpol limited state kerala india installed biogas plant use resource efficiently improve energy efficiency renewable energy using food waste company cafeteria generate biogas used prepare food cafeteria efficiently put waste use creating energy cutting biogas plant co2 emission effort reduce environmental impact distribution scope 3 terumo switching truck marine transportation improving carry efficiency distribution vehicle undertaking measure lighten environmental impact distribution terumo corporation 142 annual report 2014 improved transportation efficiency infusion product improved stacking efficiency infusion product reduce co2 emission transport stage changing specification product packaging bag using greatly improved package shape resulted 30 gain stacking capacity per pallet reducing environmental impact logistics operation important continue look way achieve higher level carry efficiency improving carry efficiency pallet level terumo corporation 143 annual report 2014 co2 emission scope 3 terumo corporation 144 annual report 2014 effective use resource earth limited resource make terumos business activity possible therefore strive utilize needed resource effectively efficiently activity associate including wastereduction effective resource utilization improved recycling making effort reduce amount landfill waste manufacturing process business activity factory rd center office generate variety waste therefore set target keeping landfill waste less 05 total amount waste generated site japan ensure achieve reduction target urge proper sorting waste continue refine waste disposal method rule fiscal 2013 04 total waste volume disposed landfill meaning achieved target tenth consecutive year target reduction landfill waste reduce amount landfill waste less 05 total amount waste generated site japan terumo corporation 145 annual report 2014 trend amount landfill waste generated japan breakdown total waste generated fy2013 terumo group operation japan reducing packaging effective use resource improved usability terumo making effort reduce packaging material without impairing functionality effort include developing smaller lighter slimmer package reviewing package design terumo corporation 146 annual report 2014 reducing paper used semisolid nutritional liquid meal adopting less compressible octagonal packing container able use thinner cardboard eliminate partition change cut amount paper used packaging 53 removal partition also make cardboard easier fold saving disposal space customer reduction cardboard volume 57 addition improved container design eliminates need use packing tape reducing weight waste reducing amount paper used packaging promoting recycling industrial waste sc one ehs expert subcommittee play big role sharing important information among site associate make effort recycle due unique property product safety concern usually possible recycle product use medical product however recycle various type waste generated production process officebased business activity use plastic product including floor tile recycled plastic fuel rpf organic fertilizer fiscal 2013 recycling rate reached 95 japan terumo corporation 147 annual report 2014 recycling amount rate japan1 recycling amount rate global 2 1 japan terumo group business location japan 2 global terumo group business location japan overseas production site initiative recycle small rechargeable battery continue recycle small rechargeable battery accordance act promotion effective utilization resource japan portable rechargeable battery recycling center terumo corporation 148 annual report 2014 jbrc promotes recycling small rechargeable battery collect recycles small rechargeable battery terumo product made several improvement simplify recycling separation process including displaying recycling logo addition collect recycle sealed leadacid battery replace maintenance collection recycling performance fy2013 april 2013 march 2014 kg nickelcadmium nickelhydride lithiumion sealed leadacid battery 6249 1207 139 1234 effective utilization water resource terumo optimize use water resource measure circulating reusing cooling water although expect production level continue rise make every effort utilize water resource effectively water use japan terumo corporation 149 annual report 2014 proper control chemical substance guided terumo global ehs policy terumo monitor control use emission disposal chemical substance according voluntary target leadership chemical substance subcommittee one ehs expert subcommittee work track reduce handling emission chemical substance target reduction chemical emission initiative aimed reducing dichloromethane emission reduce dichloromethane emission installed recovery equipment kofu factory working bring emission voluntary target less 100 ton per year target japan keep dichloromethane emission less 100 ton per year terumo corporation japan business location dichloromethane emission terumo corporation 150 annual report 2014 initiative reduce ethylene oxide emission ethylene oxide widely used sterilize medical device terumo working reduce ethylene oxide emission outside environment installed catalytic oxidation emission treatment system ashitaka fujinomiya factory shonan center along combustion treatment equipment kofu factory also working alternative ethylene oxide sterilization ethylene oxide emission data terumo corporation standalone business location japan alternative hcfc141b response montreal protocol japan prohibited domestic manufacture hcfc141b 2010 terumo established hcfc network chemical substance subcommittee 2005 year following network comprised representative factory worked alternative hcfc141b involved listing process use substance sharing information alternative sharing result study undertaken various site end 2009 completed manufacturing change accommodate alternative using 141bcontaining material already purchased although continue consume instock material purpose needing small amount substance 141b emission gradually decrease zero terumo corporation 151 annual report 2014 hcfc141b emission data terumo corporation standalone business location japan ghs initiative terumo provide ghs1 based information hazardous chemical substance associate handle chemical substance promotes proper handling chemical substance ultimately protects environment health associate also gather data prtr2 substance monthly basis work reduce source emission number one priority 1 ghsglobally harmonized system classification labelling chemical 2 prtr pollutant release transfer register terumo corporation 152 annual report 2014 management prtr substance substance volume fujinomiya ashitaka kofu rd total factory factory factory ethylene oxide gas amount used 12 627 205 01 953 eog emission 04 19 1 0 33 amount 0 0 0 0 0 transferred 12dichloroethane amount used 0 27 0 0 27 emission 0 21 0 0 21 amount 0 06 0 0 06 transferred hcfc141b amount used 14 0 0 0 14 emission 14 0 0 0 14 amount 0 0 0 0 0 transferred hcfc225 amount used 141 302 111 0 554 emission 141 241 107 0 489 amount 0 11 0 0 11 transferred dichloromethane amount used 02 128 1999 01 213 emission 02 71 703 0 776 amount 0 0 0 01 01 transferred toluene amount used 08 0 99 56 163 emission 05 0 77 0 82 amount 03 0 22 31 56 transferred terumo corporation 153 annual report 2014 substance volume fujinomiya ashitaka kofu rd total factory factory factory di 2ethylhexyl amount used 6209 35 1461 0 7705 phthalate dehp emission 0 0 0 0 0 amount 0 0 3 0 3 transferred hydrogen fluoride amount used 0 173 01 0 174 emission 0 08 0 0 08 amount 0 0 0 0 0 transferred 1bromopropane amount used 0 0 15 0 15 emission 0 0 1 0 1 amount 0 0 05 0 05 transferred nhexane amount used 0 62 0 0 62 emission 0 27 0 0 27 amount 0 35 0 0 35 transferred nndimethylformamide amount used 0 4 0 0 4 emission 0 22 0 0 22 amount 0 18 0 0 18 transferred terumo corporation 154 annual report 2014 green procurement terumo must respond wide variety demand customer government authority regarding substance control regulation various country nature medical device concern allergy endocrine disruptors cooperation among relevant department terumo working respond request building forward looking system monitoring controlling hazardous substance compliance chemical regulation worldwide reach etc response increasingly strict chemical regulation worldwide terumo developing regulatory compliance system cope future change cooperation among relevant department collection regulatory information environmental management department aggregate information environmental regulation obtained government bulletin activity industry europe advanced chemical regulation country local subsidiary also provide regular report centralizing management information terumo work ensure aware survey targeted substance regulatory response check design phasesupplier survey product design stage designer informed regulated substance refrain using environmental pollutant wherever possible use human x eco development guideline tool raise designer awareness meanwhile quality assurance department section charge material procurement cooperate investigate amount regulated substance contained material procured material investigation conducted form comprehensive survey serf wide variety purpose cover item necessary assuring product quality survey result become available quality assurance department enters database use data immediately needed terumo corporation 155 annual report 2014 humaneco development guideline feedback local site ensure local site comply regulation environmental management department provides information local subsidiary related department feedback local site aiming appropriate pcb management accordance japan law concerning special measure promotion proper treatment pcb waste waste management public cleansing law removed transformer fluorescent light ballast equipment containing pcbs japanese facility ensure prompt appropriate disposal material completed early registration toyota office japan environmental safety corporation jesco pcb polychlorinated biphenyl terumo corporation 156 annual report 2014 initiative biodiversity conservation line commitment biodiversity conservation terumo promotes activity support development lowcarbon recyclingoriented society human coexist nature mt fuji reforestation projectterumo meguminomori terumo two factory fujinomiya city shizuoka japan take water spring foot mr fuji use production process medical device pharmaceutical product recognizing use natural resource conduct business undertaken terumo mt fuji reforestation project protect area project conduct reforestation using indigenous tree part mt fuji forest lost many tree typhoon helping become resistant future natural disaster ensuring continue serve source groundwater since fiscal 2011 terumo also entered agreement shizuoka prefecture local forest owner called shizuoka mirainomori future forest supporter pact agreement plant tree maintain forested area create terumo meguminomori reserve within fumoto district fujinomiya agreement term location 165 ha forested area designated landowner fumoto district activity fujinomiya type activity forest maintenance agreement duration 5 year initiative fiscal2013 november 2013 terumo associate family member numbering 80 came together plant tree group planted 250 maple beech dogwood tree indigenous area installed shelter around sapling prevent grazing deer terumo corporation 157 annual report 2014 volunteer tree planting terumos eco challenge volunteer campaign every summer since 2006 held eco challenge campaign volunteer terumo associate japan family hold variety environmental conservation activity home work challenge sheet describing specific eco activity distributed participant perform point sunflower grown eco calculated based activity participating associate challenge participant terumo us resulting figure determine size donation organization industrial spiritual cultural advancementinternational oisca fiscal 2013 total 3090 associate participated eco challenge held together lookhowyouvegrown program participant presented minisunflower seed object combined activity raise ecological awareness participant family planting seed photographing growth sharing photo company intranet terumo corporation 158 annual report 2014 program receiving donation terumo childrens forest program childrens forest program encourages child get involved greening activity cultivate love nature learn importance forest nurturing seedling school ground community fund donated terumo used provide environmental education child philippine expand woodland planting nurturing seedling activity project restore coastal forest coastal forest play important role preserving local living condition acting sand wind barrier damper tsunami loss coastal forest due tsunami generated great east japan earthquake salt damage along coast tohoku region growing worse project restore coastal forest intended promote expanded production seedling planting nurturing forestland project also work recovery disaster affected region farmland restoration job creation terumo corporation 159 annual report 2014 environmental data fiscal 2013 green purchasing result unit yen stated thousand head office sale overall green purchase operation purchase unit 34 17 49 cost 33923 18233 54 unit yen stated thousand factory overall green purchase purchase unit 47 33 70 cost 18288 13753 75 site data manufacturing research site fiscal 2013 site location co2 water total hazardous recycled emission usage waste waste amount 1000 1000 m3 fujinomiya factory fujinomiya shizuoka japan 47 1872 3412 23 3380 ashitaka factory fujinomiya shizuoka japan 22 546 1660 203 1560 kofu factory nakakoma yamanashi japan 50 1216 4574 32 4286 ashigarakami kanagawa rd center 7 84 227 69 209 japan terumo clinical supply co kakamigahara gifu japan 09 9 43 1 35 ltd terumo corporation 160 annual report 2014 site location co2 water total hazardous recycled emission usage waste waste amount 1000 1000 m3 terumo medical corporation tcvs maryland usa 23 58 347 151 133 tcvs terumo heart inc michigan usa 3 16 499 1 91 tcvs massachusetts usa 1 1 193 0 115 harvest technology corporation massachusetts usa 03 2 361 10 186 microvention inc california usa 1 02 93 43 13 onset medical corporation california usa 01 nd nd nd nd terumo bct inc colorado usa 18 62 1511 10 1240 microvention costa rica srl san jose costa rica 01 5 11 5 6 terumo europe nv leuven belgium 15 57 840 149 362 terumo europe nv liverpool uk 02 05 185 0 75 uk plant vascutek ltd glasgow uk 2 16 129 1 46 vascutek ltd leeds uk 02 1 146 5 71 terumo bct inc larne uk 4 69 180 0 159 terumo medical product hangzhou zhejiang china 35 536 797 78 666 co ltd changchun terumo medical product jilin china 6 42 191 0 171 co ltd laguna terumo philippine corporation 25 195 1099 30 1059 philippine terumo penpol ltd kerala india 7 32 644 1 634 terumo vietnam co ltd vinh phuc vietnam 5 160 117 36 81 tcvs terumo cardiovascular system corporation waste density used calculation 02 tm3 general waste industrial waste 10 tm3 hazardous waste coefficient used calculating co 2 emission related electricity use provided electric power provider however coefficient business site marked 2005 geographic emission coeff icients presented iea co 2 emission fuel combustion 2012 figure marked revised april 20 2016 terumo corporation 161 annual report 2014 history environmental initiative 1971 environmental control department established ashitaka factory 1972 sedimentation system replaced chelating adsorption system treat water effluent containing mercury 1975 general water effluent treatment facility installed fujinomiya factory 1976 acid surface treatment needle hub base needle discontinued favor plasma treatment system generate acid wastewater fujinomiya ashitaka factory sign pollution control agreement fujinomiya city 1979 boiler fuel fujinomiya factory switched heavy oil lpg contains less sulfur 1980 syringe gasket material switched rubber thermoplastic elastomer prevent generation sulfur oxide incineration general water effluent treatment facility installed ashitaka factory 1981 ethylene vinyl acetate eva generate toxic gas incinerated adopted replace pvc polyvinyl chloride material iv solution terupack container 1982 use trichloroethylene discontinued ahead regulation 1983 gamma ray sterilization emit harmful gas adopted sterilization system kofu factory market launch nonmercury digital thermometer 1984 70 year mercury thermometer production discontinued promote use safer mercuryfree medical product 1989 glass vacuum blood collection tube replaced tube made polyester disposed incineration 1991 market launch nonpvc hypodermic administration set using polybutadiene generate hazardous gas incinerated 1992 market launch digital blood pressure monitor hospital promote use safer mercury free medical product 1994 market launch balloon catheter made thermoplastic elastomer generate sulfur oxide incinerated terumo corporation 162 annual report 2014 1996 use ozonedepleting specified chlorofluorocarbon cfc chemical eliminated kofu factory production process action later taken factory production started hypodermic administration set new type needle made plastic simplifies postdisposal separation hospital enables disposal incineration 1997 environmental management department established head office cogeneration combined heat power chp adopted cover 60 power need kofu factory fuel fujinomiya ashitaka factory switched lpg city gas emits less co2 use heavy oil discontinued production site 1998 smaller lighter syrinx introduced enabling 25 reduction waste weight use recycled copier paper implemented catalytic oxidation treatment system adopted eog emission treatment fujinomiya factory 1999 terumos basic environmental policy established cogeneration implemented fujinomiya factory recycled paper adopted use catalogue specification change notification nonpvc solution container adopted use athome continuous ambulatory peritoneal dialysis therapy polypropylene container generate hazardous gas incinerated enable 40 reduction waste weight adopted 2000 environment committee established cogeneration implemented ashitaka factory packaging container identification mark recyclable material implemented internal environmental audit implemented use dieselpowered work vehicle discontinued first edition nowannual environmental report published 2001 use incinerator discontinued kofu ashitaka factory pcbcontaining device equipment removed put storage market launch pediatric nonpvc hypodermic administration set 80 associate family member participate mt fuji cleanup activity 2002 use benzene chloroform discontinued kofu factory kofu ashitaka factory discontinue use dismantle incinerator cleanup mt fuji conducted joint activity kofu fujinomiya area 130 participant observation well installed kofu factory monitor groundwater quality market launch hypodermic administration set using totm alternative dehp plasticizer terumo corporation 163 annual report 2014 2003 zero waste emission achieved ashitaka factory head office switch lpg city gas kofu factory completes fuel conversion major site japan onsite inspection conducted overseas site terumo mt fuji reforestation project launched 2004 terumos highcalorie electrolyte infusion fluid vitamin glucose amino acid receives president prize eco product promotion council first ecoproducts award 2004 zero waste emission achieved kofu fujinomiya factory 2006 zero waste emission achieved shonan center market launch digital blood pressure monitor compliant rohs directive turbo refrigeration unit introduced kofu factory catalytic oxidation treatment system adopted eog emission treatment ashitaka factory terumo join team minus 6 2008 fujinomiya factory presented director general prize kanto bureau economy trade industry award outstanding energy conservation factory additional catalytic oxidation treatment system eog emission treatment installed ashitaka factory test plant installed liquefaction waste plastic 2009 human x eco development guideline adopted environmental auditing introduced overseas production site fujinomiya factory recognized excellence supporter 2009 ecoship modal shift project additional catalytic oxidation treatment system eog emission treatment installed fujinomiya factory 2010 solar power generation system introduced fujinomiya factory kofu factory presented highest prize kanto electricity efficiency committee chair award additional catalytic oxidation treatment system eog emission treatment installed ashitaka factory 2011 power management system providing graphic feedback adopted japanese business site high electricity consumption agreement benefitting forest shizuoka entered shizuoka prefecture japan local forest owner terumo europe haasrode plant gain iso 14001ohsas 18001 certification 2012 terumo corporation join united nation global compact terumo global ehs policy established rd center japan presented highest prize kanto electricity efficiency committee chair award 2013 fujinomiya factory terumo penpol ltd gain iso 14001ohsas 18001 certification terumo corporation 164 annual report 2014 director audit supervisory board member executive officer september 1 2014 director koji nakao yutaro shintaku chairman representative director president representative director hiroshi matsumura takayoshi mimura akira oguma hideo arase director executive vice president director senior managing executive officer director senior managing executive officer director senior executive officer president general hospital company regional representative china general affair dept regional representative latin america president ceo terumo china holding supply chain management dept president ceo terumo america holding co ltd planning dept procurement dept inc terumo call center kuniko shoji toshiaki takagi shinjiro sato david perez director senior executive officer director senior executive officer director senior executive officer director senior executive officer general manager regulatory affair dept quality assurance dept president cardiac vascular company president blood management company clinical development dept postmarket surveillance vigilance dept president ceo terumo bct inc environmental management dept tadao kakizoe mari matsunaga ikuo mori independent director independent director independent director president japan cancer society representative mari matsunaga office inc advisor fuji heavy industry ltd terumo corporation 165 annual report 2014 audit supervisory board member kenji sekine yoshiaki shiraishi toshihiko matsumiya masatake yone audit supervisory board member audit supervisory board member audit supervisory board member audit supervisory board member fulltime fulltime external external certified public accountant lawyer executive officer kazuaki kitabatake narushige toda shouji hatano yoshiaki akaike senior executive officer senior executive officer senior executive officer senior executive officer regional representative india asia general manager sale division japan general manager strategic planning dept vice president general hospital company pacific general hospital company design planning dept vice president pharmaceutical nutrition managing director terumo asia holding division production general hospital pte ltd company international business dept investor vice president dd division production relation corporate communication dept general hospital company legal dept factory manager fujinomiya pharmaceutical factory general hospital company general manager production dept tsuyoshi tomita mark sutter toru kubota somsak jarasviriyagul senior executive officer executive officer executive officer executive officer vice president general hospital company division president cv system division president terumo philippine corp representative director terumo thailand general manager business structural cardiac vascular company co ltd improvement office general hospital president ceo terumo cardiovascular company system corp kyo nishikawa hiroshi nakagomi masataka haraguchi juichi takeuchi executive officer executive officer executive officer executive officer regional representative eastern europe general manager quality assurance dept branch manager tokyo branch division president dd division overseas russia middle east africa general hospital company managing director bod chairman terumo europe n v minoru suzuki richard cappetta seiji kawabata maki takizawa executive officer executive officer executive officer executive officer general manager planning dept division president neurovascular division division president general hospital product division president general hospital product cardiac vascular company division japan general hospital company division overseas general hospital president ceo microvention inc company masato nishimura hiraku murayama ryo nishihata kosuke matsumoto executive officer executive officer executive officer executive officer general manager production technology vice president interventional system general manager treasury dept general manager human resource dept center production dept division production cardiac vascular controller dept human resource development dept company factory manager ashitaka factory cardiac vascular company masanori hoshino hiroshi nagumo jim rushworth hiroaki kasukawa executive officer executive officer executive officer executive officer president terumo clinical supply kk senior vice president general manager regional president u interventional general manager rd headquarters japan terumo bct holding corp system division cardiac vascular intellectual property dept president representative director company terumo medical pranex terumo bct kk president ceo terumo medical corp yoshihiro kimura takanori shibazaki hikaru samejima executive officer executive officer executive officer general manager internal audit dept general manager supply chain management division president interventional system dept division cardiac vascular company terumo corporation 166 annual report 2014 major consolidated subsidiary september 1 2014 japan america terumo clinical supply co ltd gifu terumo america holding inc usa terumo yamaguchi corp yamaguchi terumo medical corp usa terumo heart kk tokyo terumo cardiovascular system corp usa terumo latin america corp usa terumo medical de mexico sa de cv mexico terumo panama international inc panama terumo medical brasil ltda brasil terumo chile ltda chile terumo colombia andina sa colombia microvention inc usa terumo heart inc usa terumo bct holding corp usa terumo bct inc usa microvention costa rica srl costa rica onset medical corp usa terumo mexico service sa de cv mexico cardiac vascular business general hospital business blood management business holding company factory terumo corporation 167 annual report 2014 europe china terumo europe nv belgium terumo medical product hangzhou co ltd china terumo deutschland gmbh germany terumo china hong kong ltd china laboratoires terumo france sa france terumo medical shanghai co ltd china terumo italia srl italia terumo china holding co ltd china terumo europe españa sl spain terumo sweden private ab sweden terumo uk ltd united kingdom asia vascutek ltd united kingdom vascutek deutschland gmbh germany terumo philippine corp philippine microvention uk united kingdom tp estate inc philippine microvention europe france terumo marketing philippine inc philippine microvention deutschland gmbh germany terumo thailand co ltd thailand terumo bct europe nv belgium terumo vietnam co ltd vietnam terumo russia llc russia pt terumo indonesia indonesia terumo bct ltd united kingdom terumo korea corp korea terumo penpol ltd india terumo mauritius holding ltd mauritius terumo asia holding pte ltd singapore terumo singapore pte ltd singapore terumo malaysia sdn bhd malaysia terumo australia pty limited australia terumo vietnam medical equipment co ltd vietnam terumo bct vietnam co ltd vietnam terumo india private ltd india terumo corporation 168 annual report 2014 corporate information september 1 2014 tokyo office tokyo opera city tower 3202 nishishinjuku shinjukuku tokyo 1631450 japan head office 2441 hatagaya shibuyaku tokyo 1510072 japan founded september 17 1921 capital 387 billion yen employee 19263 nonconsolidated 4764 march 31 2014 terumo group website wwwterumocom annual report 2014 wwwterumocominvestorlibraryannualreport investor information march 31 2014 number share authorized 840000000 number share issued 189880260 number stockholder 30034 stock exchange listing first section tokyo stock exchange security code 4543 trading unit 100 share terumo corporation split share common stock two share effective 1st april 2014 composition issued share type stockholder major shareholder top 10 shareholder number percentage treasury share share held total thousand share issued 00 master trust bank japan ltd trust 16170 852 individual others trust bank japan trustee service bank ltd trust 10144 534 958 banking company daiichi life insurance company limited 10129 533 2913 meiji yasuda life insurance company number 6958 366 foreign share issued company tokio marine nichido fire insurance co ltd 6804 358 2876 189880260 mizuho bank ltd 5376 283 financial institution olympus corporation 4715 248 1715 mitsubishi ufj trust banking corporation 3831 202 terumo life science foundation 3680 194 company security company 1111 427 bnp paribas security japan limited 3493 184 terumo terumo bct misago hiryu nobori ultimaster nanopass surflo surplug chemoshield f2 light terumeal lunawave hr joint acelio glide sheath slender registered trademark terumo corporation mermed trademark terumo corporation fred registered trademark microvention inc scepter trademark microvention inc mirasol registered trademark terumo bct biotechnology llc spectrum optia trademark terumo bct inc terumo corporation 169 annual report 2014 reporting policy corporate mission report created intuitively share information stakeholder terumos business activity conducted corporate mission contributing society healthcare promote communication society feature introduces initiative developing endovascular treatment apheresis therapy illustrate terumos stance realizing corporate philosophy moreover starting fiscal year new section environmental health safety ehs added report content scope report report carry data terumo group company japan overseas presented consolidated basis wherever possible albeit exception depending data item report period fiscal 2014 april 1 2013 march 31 2014 activity reported include recent activity publication schedule report july 2014 previous report august 2013 next report august 2015 tentative referenced guideline gri sustainability reporting guideline standard disclosure japanese ministry environment environmental reporting guideline 2012 version report archive past report year available pdf format web site terumo corporation 170 annual report 2014 tokyo office terumo corporation october 2014 tokyo opera city tower 3202 nishishinjuku shinjukuku tokyo 1631450 japan 14t419 printed japan